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ABSTRACT 
Glomerulonephritis (GN) is the main cause of chronic kidney disease (CKD) in patients on renal 
replacement therapy, with IgA nephropathy (IgAN) being the most frequent single diagnosis. Patients 
with reduced kidney function and/or proteinuria have an increased risk of premature cardiovascular 
disease (CVD). Based on the assumption that progression of atherosclerosis and glomerulosclerosis share 
similar pathogenetic mechanisms, the aim of this thesis was to investigate to which extent some of the 
described traditional and non-traditional cardiovascular risk factors are also predictors of renal outcome in 
patients with a homogenous renal diagnosis, e.g. IgAN. Chronic inflammation is supposed to be one of the 
driving forces in renal disease progression, and disturbances in both innate and adaptive immunity seem to 
be involved in the pathogenesis of IgAN, with T-lymphocytes being of particular interest. We therefore 
also investigated the prognostic impact of plasma levels of soluble interleukin-2 receptor, suggested as a 
marker of continuous T-cell stimulation.   
   
Study I was a pilot study, investigating activated monocytes (MOs) as one possible source of oxidative 
stress in IgAN. Peripheral blood MOs from 16 patients with IgAN and 16 healthy controls were 
stimulated in vitro and the production of reactive oxygen species (= respiratory burst) was measured by 
flow cytometry. In the patients, this was repeated after one month‟s treatment with 20 mg atorvastatin. At 
baseline, the respiratory burst of in vitro stimulated MOs was higher in patients as compared to in healthy 
controls. After atorvastatin treatment, there was a significant reduction of unstimulated and stimulated 
MO respiratory burst compared to baseline values. 
 
 In study II, the apolipoprotein B /apolipoprotein A-I ratio ( apoB/apoA-I), indicating the balance of 
atherogenic and anti-atherogenic lipids, was analyzed in 70 IgAN patients with CKD stage 1-3 (estimated 
glomerular filtration rate (eGFR) ≥ 30ml/min/1.73m²) and in 70 age- and gender matched healthy control 
subjects. Patients with IgAN had higher serum levels of apoB/apoA-I compared to the controls, and an 
apoB/apoA-I ratio greater than the proposed threshold value of 0.9 for men and 0.8 for women was 
associated with an increased risk for the development of end stage renal disease (ESRD) in the patients, 
after a median follow-up period of 3.8 years.   
 
Study III comprised 194 patients with IgAN, of whom 179 with CKD stage 1-4 (eGFR ≥15ml/min/ 
1.73m²) had been prospectively followed for up to 16 years (median 52 months). Plasma levels of soluble 
interleukin-2 receptor alfa unit (sIL-2Ra) were higher in IgAN patients compared to in 84 healthy 
controls. In survival analysis, baseline sIL-2Ra levels in the upper tertile predicted worse renal outcome in 
IgAN patients. Soluble IL-2Ra also correlated to the rate of renal function decline (annual eGFR slope). In 
51 patients, in whom the renal biopsy had been scored according to the new Oxford classification, higher 
IL-2Ra levels were associated with the presence of more than 25% tubular atrophy/ interstitial fibrosis (T 
score 1-2), after adjustment for renal function.     
    
Study IV was performed in 180 IgAN patients with CKD stage 1-4, followed for a median of 55 months. 
Baseline serum levels of fibroblast growth factor 23 (FGF23), a key player in the chronic kidney disease-
mineral and bone disorder (CKD-MBD), were associated with severe renal outcome and with the annual 
eGFR slope. Moreover, the FGF23 level at baseline correlated to the degree of albuminuria at baseline and 
to time-averaged albuminuria during follow-up, a new finding that implicates possible direct effects of 
FGF23 on the glomerular filtration barrier.      
 
In Summary, several factors involved in the progression of atherosclerosis are also present and predictive 
of renal outcome in patients with IgAN, independent of the confirmed main risk factors: proteinuria and 
hypertension. Furthermore, continuous T-cell stimulation may contribute to renal disease progression in 
IgAN. The investigated potential biomarkers could be useful in the monitoring of the therapy.                                                                             
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BACKGROUND 
1.1 INTRODUCTION 
A diagnosis of chronic kidney disease (CKD) is made, irrespective of cause, based on one of the 
following criteria proposed in 2002 by the National Kidney Foundation and Kidney Disease 
Outcomes Quality Initiative (NFK-KDOQI) and endorsed by the Kidney Disease: Improving 
Global Outcomes (KDIGO) in 2004 (1, 2):  
 
 
 
 
 
 
 
 
 
 
 
The prevalence of CKD in the general population is appreciated to be about 10-13% (3-5) with a 
greater risk in individuals with a family history of CKD (6). Patients suffering from CKD have 
an increased risk of death due to cardiovascular disease (CVD) such as myocardial infarction, 
heart failure, sudden cardiac death or stroke, with the highest risk in those who develop end stage 
renal disease (ESRD) requiring chronic dialysis or a kidney transplant (7, 8).  
 
CKD is currently classified by the five stages defined in 2002, which reflect patient prognosis 
and should lead to recommended clinical action plans to prevent CKD progression and to reduce 
the risk of CVD (Table 1) (1).  
 
Table 1. Classification of CKD stages and recommended clinical action plan 
 
Stage Description GFR 
(mL/min/1.73m²) 
Action 
 At increased risk ≥ 90 
(with CKD risk factors) 
Screening, 
CKD risk reduction 
1 Kidney damage with 
normal or ↑ GFR 
≥ 90 Diagnosis and treatment, 
Treatment of comorbid conditions, 
slowing progression, 
CVD risk reduction 
2 Kidney damage with 
mild ↓ GFR 
60 - 89 Estimating progression 
3 Moderate ↓ GFR 30 - 59 Evaluating and treating complications 
4 Severe ↓ GFR 15 - 29 Preparation for kidney replacement 
therapy 
5 Kidney failure < 15 
(or dialysis) 
Replacement (if uremia present) 
 
1. Kidney damage for ≥ 3 months, as defined by structural or 
functional abnormalities of the kidney, with or without 
decreased GFR, manifest by either: 
a. Pathologigal abnormalities; or 
b. Markers of kidney damage, including abnormalities in 
the composition of the blood or urine, or abnormalities in 
imaging tests 
2. GFR < 60mL/min/1.73m² for ≥ 3 months, with or without kidney 
damage  
 2 
The high prevalence of CVD among incident dialysis patients suggests that pathologic 
cardiovascular changes begin in earlier stages of CKD, and that implementation of risk factor 
reduction strategies earlier in the course of CKD may provide an opportunity to prevent CVD. 
The risk factors for CKD and CVD are, in many instances, the same and it is generally assumed 
that atherosclerosis and glomerulosclerosis display similar pathogenetic mechanisms (9-11). 
However, the presence of traditional risk factors for CVD, such as old age, smoking, 
hypertension, diabetes mellitus, dyslipidemia, and left ventricular hypertrophy, as described 
primarily in the Framingham study, does not seem to provide a satisfactory explanation for the 
huge cardiovascular burden in the CKD population. Other so-called non-traditional risk factors, 
such as chronic inflammation, oxidative stress, altered calcium-phosphate metabolism and 
malnutrition seem to appear early during the process of CKD and to contribute to the significant 
difference in cardiovascular mortality between individuals with CKD and those without (12-14).  
 
There is emerging evidence for lower estimated glomerular filtration rate (eGFR) and higher 
albuminuria as being independent risk factors for CVD, mortality, progressive CKD and ESRD 
(15-17). As a consequence, the recent work of a KDIGO initiated Controversies Conference has 
led to the proposal of a modified classification of CKD, adding albuminuria stage (A1: 
optimal and high-normal, albumin-to-creatinine ratio (ACR) < 30 mg/g; A2: high, ACR 30 – 299 
mg/g; A3: very high and nephrotic, ACR > 300 mg/g), subdividing CKD stage 3 in 3a (eGFR 
45 -59 ml/min/1.73m²) and 3b (eGFR 30 – 44 ml/min/1.73m²) and emphasizing the clinical 
diagnosis (diabetes, hypertension, glomerular disease, many others, transplant, unknown) (18). 
The threshold of eGFR 45 ml/min/1.73m² for subdividing CKD stage 3 was chosen due to the 
substantial increase in risk of cardiovascular morbidity and mortality found in patients with renal 
function below this value (19). 
 
The proteinuric diseases glomerulonephritis, diabetic nephropathy and 
hypertensivenephrosclerosis are all major causes of CKD leading to ESRD. Glomerulonephritis 
is the main cause of CKD in patients treated with dialysis or a kidney transplant in the Swedish 
population (Swedish Renal Registry, www.snronline.se). Among those, IgA nephropathy (IgAN) 
is the most frequent diagnosis of glomerulonephritis, confirmed by renal biopsy. 
In patients with IgAN, an increased risk of developing CVD compared to age-matched 
individuals in the general population has been shown by Myllymaki et al (20). 
 
The aim of the studies in this thesis was to investigate to what extent some of the described 
traditional and non-traditional cardiovascular risk factors are also present and are predictors of 
renal outcome in patients with IgAN. 
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1.2 IGA NEPHROPATHY  
IgA nephropathy was described histologically for the first time in 1968 by Berger and Hinglais 
by its characteristics of dépôts intercapillaires d’IgA-IgG (intercapillary deposits of IgA-IgG) 
(21). The diagnosis also requires the presence of mesangial proliferative changes.   
 
1.2.1 Epidemiology 
IgA nephropathy is the most common form of primary glomerulonephritis world-wide with an 
annual incidence rate of at least 25/million in adults, varying between different countries (22, 
23). There are no discernible trends in incidence rates over time. The disease can exist 
subclinically and is therefore only detected by chance in some patients (24). Racial differences 
and referral policies for diagnostic biopsy can affect the incidence rates found. In a screening 
study among children (0-15 years) in Japan 45 children/million/year were diagnosed with IgAN 
(25). Moreover, 16% of 510 kidneys from apparently healthy kidney donors showed 
histopathological changes diagnostic for IgAN (26). There is a peak incidence in the second and 
third decades of live and men are more frequently affected by IgAN than women, with a ratio 
ranging from 2:1 to 6:1 (27).  
 
1.2.2 Clinical presentation 
The archetypical clinical presentation of IgAN is that of a young male patient with episodic 
macroscopic hematuria during an upper respiratory tract infection, which is the presenting 
feature in 30 – 40% of cases. Such episodes usually recur for some years but disappear over time. 
Another 30 – 40% of patients with IgAN are identified by asymptomatic urine abnormalities. 
Only a few patients have proteinuria without microscopic hematuria. About 5% of all patients 
develop a nephrotic syndrome that can appear both together with mild glomerular injury and in 
advanced glomerulosclerosis. Less than 5% of all patients with IgAN present with acute renal 
failure due to crescentic nephritis or due to tubular occlusion in heavy glomerular hematuria (28). 
The remaining patients with IgAN already have renal impairment and hypertension, sometimes 
of a malignant nature, at the time of diagnosis, presumably due to longstanding unrevealed 
disease.   
 
1.2.3 Pathogenesis 
The broad spectrum of clinical pictures and the varying associations found with genetic risk 
alleles among different populations make IgAN appear to be a clinicopathological phenotype, 
and the result of a variety of etiologic and pathogenetic factors (24). Interestingly, IgA 
nephropathy in the ddY mouse model shows similar variability, including asymptomatic, early 
and late-onset overt disease (29). Most probably, there is a hereditable component in IgAN, but 
additional factors are needed to produce overt renal disease.  
 
It has been shown that four main processes contribute to the development of IgAN:  
1. A genetically determined increase in circulating levels of galactose-deficient IgA1 (Gd-
IgA1)  
2. Synthesis of IgG and IgA antibodies directed against Gd-IgA1  
3. Formation of circulating, polymeric Gd-IgA1 containing immune-complexes  
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4. Deposition of these immune-complexes in the kidney, leading to activation of mesangial 
cells, characterized by proliferation and secretion of extracellular matrix, cytokines and 
chemokines which further promote the renal injury (30-33).  
 
How these processes may interact with other pathogenetic mechanisms, as described below, is 
illustrated in a recently published review article by Boyd et al (Figure 1) (34). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Reprinted with permission from Macmillan Publishers Ltd:  Boyd JK, Cheung CK, Molyneux K, Feehally J, Barratt J.   
An update on the pathogenesis and treatment of IgA nephropathy. Kidney international. 2012 Feb 8.  
Figure 1. An overview of the pathogenesis of immunoglobulin (Ig)A nephropathy. (1) Mucosal 
infection primes naive B cells to class switch to become IgA
+
 antibody-secreting cells (ASCs) through 
both T-cell–dependent (cytokine mediated) and T-cell–independent (Toll-like receptor (TLR) 
ligation) pathways. (2) Some IgA
+
 ASC mis-home to the systemic compartment during lymphocyte 
trafficking. (3) Displaced IgA
+
 ASCs take up residence in systemic sites and secrete normal 
‘mucosal-type’ (poorly galactosylated and polymeric) IgA1 into the systemic circulation. (4) IgA1 
secretion by displaced mucosal ASC is augmented by TLR ligation from mucosal-derived pathogen-
associated molecular patterns, which have entered the systemic compartment. (5) IgA1 immune 
complexes form in the systemic circulation. Poorly galactosylated polymeric IgA1 molecules are the 
substrate for immune complex formation and combine with: (a) IgG and IgA autoantibodies reactive 
to exposed neoepitopes in the poorly galactosylated IgA1 hinge region; (b) antimicrobial antibodies 
specific for carbohydrate components of the microbial cell wall, which are cross-reactive with the 
poorly galactosylated IgA1 hinge region; (c) soluble CD89 that is shed from myeloid cells in response 
to polymeric IgA1 binding. (6) IgA1 immune complexes deposit in the mesangium through a 
combination of mesangial trapping and increased affinity of poorly galactosylated IgA1 for 
extracellular matrix components. Immune complex deposition triggers a series of downstream 
pathways leading to glomerular injury and tubulointerstitial scarring. 
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1.2.3.1 Genetic predisposition 
Genome-wide association studies by Suzuki and Gharavi et al have identified five distinct 
susceptibility loci in the MHC locus on chromosome 6p21, the complement factor H locus on 
chromosome 1q32, and in a cluster of genes on chromosome 22q12 playing a potential role in 
antigen presentation, the formation of Gd-IgA1 and the cleaning of immune complexes by the 
alternative complement pathway (33, 35). The frequency of these genetic variants could to some 
extend explain the differences in prevalence rates of IgAN across different continental 
populations.  
Recently, studies in Italy found a genetic predisposition to sporadic IgAN by polymorphisms in 
the genes C1GALT1 (coding for core-1-β,3-galactolsyltransferase, responsible for IgA 
galactosylation) and TLR4 (coding for Toll-like receptor 4) (36). In familial IgAN, genetic 
heterogeneity had been found with regard to the linkage to IGAN1 locus on chromosome 6 (37, 
38). In minor patient cohorts, the susceptibility to IgAN has also been associated with variations 
in other genes such as those coding for transforming growth factor-beta 1, for angiotensin 
converting enzyme or, in males, for angiotensinogen (39-41). 
 
1.2.3.2 Mucosal and systemic production of IgA1  
Most of the systemic IgA in humans consists of the subtype 1. The monomeric form of IgA1 is 
released by the bone marrow, lymph nodes and spleen. Polymeric IgA1 is produced mainly by 
lymphocytes and plasma cells in the respiratory and gastrointestinal tracts.  Abnormalities in the 
mucosal response to common microbial or alimental antigens may be involved in the synthesis of 
aberrantly glycosylated IgA1 as described below (42-44) and underglycosylated IgA1 is more 
prone to aggregate to polymeric forms (31, 45). The mucosal surface is the main site of the 
innate immunity, including the recognition of pathogen-associated molecular patterns (PAMPs) 
by macrophages, dendritic cells or leukocytes, preferably through binding to Toll-like receptors 
(46, 47). The innate immunity further links to the adaptive immunity by dendritic cell maturation 
and antigen-presentation to T-lymphocytes, leading to stimulation of antibody synthesis by B-
cells. A dysregulation of both innate and adaptive immunity in IgAN may result in decreased 
mucosal antigen elimination and /or altered IgA1 synthesis promoting chronic inflammation 
(46). „Homing‟ of CD4 positive T-cells and polymeric IgA1 (pIgA1) producing plasma cells 
from mucosal to systemic sites has been discussed as being contributory factors of the increased 
release of pIgA1 into the circulation in IgAN (48-51).  
 
1.2.3.3 Aberrant glycosylation of IgA1 
All immunoglobulins, including IgA1 are glycosylated. An altered pattern of the glycosylation of 
IgA1 has been recognized as a potential pathogenetic factor in IgAN for about two decades. It is 
driven by abnormalities of the expression and activity of the glycosyltransferases involved in the 
sequential post-translational modification of IgA1(52). The key feature of IgAN is the deficiency 
of galactose in the hinge region of the IgA1 heavy chains, exposing abbreviated glycans, 
composed of N-acetylgalactosamine (GalNAc) (Figure 2). These can be detected by ELISA 
methods using a GalNAc-specific lectin, Helix aspera agglutinin (53). Elevated circulating levels 
of Gd-IgA1 are found in patients with IgAN and in their relatives in comparison to in healthy 
controls (54). In patients with IgAN, the Gd-IgA1 is also detected in tonsillary B- cells (55-57) 
and in the immune-complexes deposited in the mesangium (58, 59).  
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1.2.3.4 Galactose-deficient IgA1- containing immune complexes and mesangial proliferation 
Aberrantly glycosylated IgA1 can trigger an IgG autoimmune response forming IgG/IgA1 
immune complexes (ICs) (52). „Molecular mimicry‟ from environmental agents (such as 
ubiquitous bacterial and viral envelope proteins) is supposed to be involved in the autoantibody 
response to the neo-antigenic GalNac sites in the aberrant IgA1 (24). Serum values of IgG 
specific for Gd- IgA1 may serve as a more sensitive biomarker for IgAN than the levels of IgA1 
itself (52, 53). 
In IgAN, large IgG-IgA1 ICs are formed which likely escape clearance by hepatic receptors and 
enter the renal circulation where they pass through the endothelial fenestrae in the glomerular 
capillary wall and react with fibronectin, laminin and collagen within the mesangial matrix (31, 
60, 61). It is not yet known what the pathogenetic role is of the transferrin receptor (CD71), 
which is expressed on the surface of proliferating human mesangial cells and can bind polymeric 
IgA1 as well as ICs containing Gd-IgA1. Binding of the ICs enhances the expression of the 
CD71 receptor in a positive feedback loop (62-64).  
As shown by in vitro studies, the IgG-IgA1 immune complexes induce the mesangial cells to 
proliferate, secrete extracellular matrix components and release humoral factors such as tumor 
necrosis factor alpha (TNFα), interleukin-6 (IL-6), transforming growth factor beta (TGFβ), 
platelet derived growth factor (PDGF) and angiotensin II which further promote inflammation 
and enhanced glomerular permeability (65, 66). Complement activation via the alternative or 
mannose-binding lectin (MBL) pathway contributes to the renal damage (67-70). 
The biologic activity of the galactose-deficient IgA1-containing ICs, assessed by their in vitro 
effect on mesangial cell-proliferation, increases in IgAN patients during episodes of macroscopic 
hematuria (71). 
In serum, pIgA can also be found in ICs bound to a soluble form of the IgA-specific receptor 
CD89 (sCD89-pIgA ICs) that is normally expressed on the surface of monocytes, macrophages, 
neutrophils, eosinophils, dendritic cells and hepatic Kupffer cells but not mesangial cells and that 
belongs to a class of receptors that bind the Fc portion of immunoglobulins (72). Repeated 
samples in patients with IgAN, participating in the follow-up study at our department, showed 
consistently lower levels of sCD89-pIgA ICs, containing the 30kDa isoform of CD89, in patients 
with progressive disease compared to patients with more stable disease. A genetic single 
nucleotide polymorphism (SNP) associated with the lower levels of sCD89-pIgA ICs (73). This 
leads to the speculation that the binding of pIgA to sCD89 might protect from IgG-IgA1 
immune- complex formation and secondary pathogenetic mechanisms (73, 74).  
 
 
 
 
 
 
 
 
 
 
  
 
Figure 2. Galactose-deficient IgA1 
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1.2.3.5 Podocyte injury in IgAN 
IgAN often shows lesions morphologically identical to those of focal segmental 
glomerulosclerosis (FSGS). According to recent studies, the segmental sclerotic lesions have 
features that suggest that they are due to primary podocyte injury (75, 76). It has been shown that 
aggregated IgA1 from patients with IgAN inhibits nephrin expression in podocytes (77, 78), 
mediated through TNFα and platelet-activating factor (PAF) (65, 79), and appears to produce 
podocyte apoptosis (66), as well as reduced adhesive capacity (80). Immunohistochemical 
studies in IgAN showed, in similarity to studies on FSGS, a focal loss of the podocyte markers 
synaptopodin, glomerular epithelial protein1 (GLEPP-1), nephrin and vascular endothelial 
growth factor (VEGF), particularly at sites of capsular adhesions without histological changes in 
the underlying glomerular tuft (76). The presence of free, podocyte marker bearing cells in 
Bowman´s space and the cumulative excretion of podocytes in the urine, linked to the prognosis 
of IgAN, all support the essential role of podocyte damage in IgA nephropathy (76, 81, 82). 
 
 
1.2.4 Diagnosis and histopathologic classification  
Until we have access to reliable noninvasive diagnostic tests, a diagnosis of IgAN requires a 
renal biopsy. Histopathological findings also contribute to the estimation of inflammatory 
activity and irreversible chronic changes. The value of this information for clinical decision 
making with respect to treatment is currently under intensive investigation. 
 
Mesangial IgA deposits are the defining hallmark of the disease. IgG and IgM may accompany 
IgA but are found to a lesser extent. C3 deposition usually has the same distribution as IgA in the 
glomerulus and is also found in the wall of extraglomerular small vessels (83). The most 
common appearance in light microscopy is mesangial hypercellularity and accumulation of 
mesangial matrix. Crescentic changes may be superimposed on diffuse mesangial proliferative 
changes with or without associated segmental necrosis. Tubulointerstitial changes are similar to 
those seen in other forms of progressive GN, reflecting the final common pathway of renal 
parenchymal disease. Arteriolar vessel changes with hyaline atherosclerosis and media 
hypertrophy are frequently already found in early stages of CKD (84). 
 
There has been a lack of international consensus in the validation of previous histopathological 
classifications (83, 85-88). In the new Oxford classification (OXFORD-MEST score) the 
International IgA Nephropathy Network has identified four histopathological lesions of 
independent prognostic importance; mesangial (M) and endocapillary (E) hypercellularity, 
segmental glomerulosclerosis (S), tubular atrophy and interstitial fibrosis (T). The results were 
analyzed using a systematic approach in order to develop a reproducible classification which 
could predict clinical outcome (89, 90). This classification has been validated in a number of 
different patient cohorts, adults and children (91-100), and some questions have been raised 
about the lack of cases with either milder or the most aggressive forms of the disease in the 
Oxford patient cohort, including cases with significant extracapillary proliferation. The large 
ongoing international multicenter VALIGA study, including more than 1200 patients with all 
spectrums of the disease, may lead to a new version of the Oxford classification. Figure 3 shows 
typical histopathological findings as described by the Oxford-MEST score: 
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Mesangial proliferation (M)                         Endocapillary proliferation (E) 
 
 
 
 
 
 
 
 
 
 
 
Segmental glomerulosclerosis (S)               Tubular atrophy and interstitial fibrosis (T) 
 
Figure 3: Histopathological lesions scored according to the Oxford-MEST classification 
 
 
1.2.5 Natural history 
Most published studies report on approximately 25 – 30% of patients requiring renal replacement 
therapy within 20 – 25 years of presentation and about 15% of patients within 10 years. Fewer 
than 10% of all patients with IgAN had complete resolution of urinary abnormalities, 
spontaneously or after treatment in most reports (27, 101-104). Repeated biopsy studies confirm 
that glomerular changes, including IgA deposits, can completely disappear spontaneously or after 
treatment in both native (105-107) or transplanted kidneys (108, 109). Contrary to what was 
previously thought, the disease seems to be as progressive in children as in adults (101, 110-112). 
Recurrence of IgAN after kidney transplantation occurs in about one third of patients, with large 
discrepancies between different series, mainly due to varying indications for graft biopsy and 
differences in follow-up duration as reviewed by Ponticelli 2010 (113). A clinical diagnosis of 
recurrent IgAN is made on average three years after transplantation. Recurrence is more frequent 
in younger patients and in those with a rapid progression of the original disease (109, 114, 115).  
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1.2.6  General mechanisms of renal disease progression 
A number of sequential pathophysiological mechanisms have been identified as contributing to 
renal disease progression in general, presented by Harris and Neilson, Schlondorff and Sung et al 
(116-118) and they are summarized here:  
1) Persistent glomerular damage due to inflammation or ischemia or a lower number of 
functioning nephrons from the outset, as seen in individuals with low birth weight.  
2) Hyperfiltration in the remaining glomeruli with the loss of autoregulatory mechanisms. This 
results in the transfer of systemic hypertension to high intraglomerular pressure, contributing to 
glomerular and tubular hypertrophy. Epithelial cells (podocytes) can no longer cover the whole 
hypertrophied glomerulus and naked capillary loops lead to focal adherences to Bowman‟s 
capsule epithelium, more central parts of the capillary loop sclerose.  
3) Hyperfiltration, also driven by metabolic factors like high glucose levels or a high protein 
load, promotes proteinuria. Hemodynamic changes contribute to a higher glomerular expression 
of cytokines and chemokines like interleukin-1 (IL-1), TNFα, monocyte chemoattractant protein-
1 (MCP-1) or macrophage inhibitory factor (MIF), stimulating leukocyte-, trombocyte- and, 
further on, macrophage- and lymphocyte accumulation. 
4) Proximal tubular cells are exposed to an amount of activating substances, not normally 
filtrated, like proinflammatory cytokines, chemokines, complement, ferritin, albumin-bound 
lipopolysaccharides, free fatty acids, immunoglobulins or growth factors such as insulin-like 
growth factor-1 (IGF-1) or TGFβ. Iron-complexes can contribute to oxidative damage. Also, 
there will be an overload of small proteins, normally reabsorbed by proximal tubular cells 
through endocytosis. 
5) Growth factors and chemokines, filtrated and/or produced by activated tubular cells lead to the 
recruitment of neutrophils and macrophages that, in turn, produce cytokines and chemokines 
and induce tubular apoptosis. Fragments from filtrated proteins and necrotic cell components, 
which have been degraded by the tubular cells‟ proteasomes, are internalized by activated 
dendritic cells which, in turn, migrate to the renal lymph system and present those protein 
fragments as „danger signals‟ (DAMPS) to cytotoxic T-cells through MHC klass II antigen 
presentation. The consequence is a successive loss of self-tolerance. Through these mechanisms, 
tubular atrophy and interstitial inflammation increase and nephritogenic T-cells accumulate. 
„Pore forming proteins‟ (perforin, serin, esteras), produced by T-cells, lead to a higher 
permeability of the basement membrane. Similar effects are seen due to Toll-like receptor (TLR) 
activation through infections, metabolic factors, bacterial or viral ligands or free RNA from 
damaged cells. A cross-reaction with epitopes in the interstitium can also lead to immune-
deposition. Accordingly, complement is activated both by the classical and the alternative 
pathway.  
 
6) The increased stress on tubular cells through the overload of their endoplasmatic reticulum 
(tubular ER stress) and a structural change of the cells‟ cytoskeleton makes them transform to 
fibroblasts through so-called epithelial-mesenchymal transition (EMT). Those newly formed 
fibroblasts produce collagen molecules/matrix between the vasa recta and the tubular nephron 
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with negative impact on the survival conditions for the remaining tubular cells and ischemic 
damage to surrounding vessels. A disturbance of the balance between growth-factors and the 
proliferation of local fibroblasts can contribute to the damage, terminally leading to non-cellular 
scar formation.  
Angiotensin II (Ang II) activation contributes to all these processes in a crucial way: by 
vasoconstriction of the efferent arteriole, Ang II activation leads to increased glomerular 
pressure, while vasoconstrictor effects on the afferent arteriole are counteracted by vasodilators 
such as nitric oxide (NO) and prostaglandins. Ang II effects also involve a reduction of the 
glomerular filters‟ size-selectivity and an increase of intracellular calcium in podocytes which 
contributes to changes in the cellular cytoskeleton. 
 
Vascular endothelial cells produce cytokines, chemokines, growth factors and procoagulant 
factors in response to „shear stress‟ which leads to trombocyte aggregation, and microtrombi, 
endothelial degeneration and hyaline depositions in the vascular wall as well as an 
inflammatory reaction with neutrophil-adhesion and macrophage-infiltration. 
 
Important with regard to IgAN are the findings that even mesangial cells, after activation and 
proliferation, can develop into a fibroblast-phenotype with production of collagen, fibronectin, 
laminin, proteases and cytokines [IL-1, MCP-1, Regulation on Activation, Normal T Expressed 
and Secreted (RANTES), PDGF, TGFβ among others]. 
 
The general CKD progression theory, based on hemodynamic, proteinuric and inflammatory 
mechanisms secondary to nephron loss, is also relevant in IgAN as has been evaluated by a 
study by Bazzi et al (119). They found the ratio of the fractional excretion of IgG to the 
percentage of non-globally sclerotic glomeruli (FEIgG/SG) to be a reliable marker of tubular 
protein load in surviving glomeruli and a predictor of renal outcome.  
Figure 4 provides an overview of the general mechanisms involved in renal disease progression 
and the focus of the studies included in this thesis.  
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Figure 4: General mechanisms of renal disease progression and focus of the four studies included in 
the thesis: Paper I and II: metabolic injury, Paper III: activation of T-cells, Paper IV: disturbed 
tubular mechanisms. Mo, monocyte; MØ, macrophage; DC, dendritic cell; T-cell, T-lymphocyte; EMT, 
epithelial-mesenchymal transition.  
Adapted from Schlondorff DO Kidney Int 2008.74:860-866 and Harris RC and Nelson EG, Ann Rev 
Med 2006.57:365-80  
 
 
1.2.7 Risk markers for renal disease progression in IgAN 
In an attempt to identify patients at higher risk for renal disease progression and therefore 
requiring more intensive follow-up and treatment, different scoring systems have been generated, 
as reviewed by Berthoux et al in 2011 (120) . Most of them include histopathological findings, 
making them more applicable at the time of diagnosis than during clinical follow-up. One of the 
difficulties in the prediction of prognosis in an individual patient with IgAN is the uncertainty 
about the disease course prior to the awareness of clinical symptoms leading to the diagnosis. 
This is illustrated by the findings that the impact of the major known risk factors, namely higher 
levels of proteinuria, serum-creatinine and blood pressure, varies depending on their onset, 
duration and possible relapse during the disease course (103, 104, 111, 121). The response of 
these parameters to therapy during follow-up is a strong indicator of renal outcome as is the 
presence or absence of advanced renal histopathological findings such as glomerular sclerosis 
and tubulo-interstitial fibrosis. 
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Smoking, hyperlipidemia, obesity, hyperinsulinemia and hyperuricemia have all been associated 
with renal disease progression in IgAN and other forms of chronic renal disease (122-128). 
Moderate alcohol intake may, however, be protective (129).  
Little is known about the pathogenetic role and prognostic value of isolated inflammatory 
markers in blood or urine in IgAN. Some of the recent findings are presented in the „General 
Discussion‟ part of this thesis. Markers of oxidative stress are discussed below. No differences 
between the sexes have been found with regard to renal outcome in IgAN which is in contrast to 
other forms of chronic GN (130). 
 
Immunostaining of a subgroup of the renal biopsy specimens examined in the Oxford 
classification study cohort showed a possible impact of the distribution of IgA and IgG deposits 
in the glomerulus on the presence of proliferative lesions (131). The presence of capillary wall 
IgA deposits in addition to mesangial IgA deposits and the presence of IgG deposits were 
associated with a higher mesangial cellularity score and with the presence of endocapillary 
proliferation, supporting a causative role of these deposits in the development of proliferative 
changes. No significant association to renal outcome was found which might have been biased 
by treatment, as capillary wall IgA and the presence of IgG were associated with trends towards 
greater immunosuppression. Notably, in earlier studies, when RAAS blockade and 
immunosuppressive treatment were applied to a lesser extent, the extension of IgA deposition 
from the mesangial area to the peripheral capillary wall was found to be a significant adverse risk 
factor for renal disease progression (101). As a consequence, the location of IgA and IgG may be 
a factor to be taken into consideration in the prediction of prognosis and the decision on 
treatment but this has to be further validated. 
   
 
1.2.8 IgAN associated to Henoch-Schönlein purpura 
 
IgAN is closely associated with Henoch-Schönlein purpura (HSP), a small vessel vasculitis with 
deposition of IgA, predominantly affecting the skin, joints, gut and kidney (132). The nephritis of 
HSP (HSPN) is, like IgAN, characterized by mesangial deposition of galactose-deficient IgA1- 
containing immune complexes and is histologically indistinguishable from IgAN, though often 
showing more active proliferative and necrotic lesions (133, 134). Patients with HSPN have been 
documented in several pedigrees of related patients with IgAN (135, 136). Recently, a 
heritability of serum Gd-IgA1 has been shown in children with HSPN and children with IgAN 
(137) as has earlier been shown in adults with IgAN (54). 
Due to the shared pathogenetic mechanisms, IgAN and HSPN are regarded by most authors as 
different clinical manifestations of one systemic disease. It is not uncommon that the same 
patient initially has clinical symptoms of Henoch-Schönlein purpura-associated nephritis, often 
with a good response to low doses of Prednisolone, if needed, but later on develops a more 
typical picture of chronic IgAN. The renal function can deteriorate many years after apparent 
remission which makes it mandatory to follow all patients for at least 5 – 10 years and to follow 
children with apparently benign HSPN or IgAN when they become adults (138, 139).  
In most of the studies presented in this thesis both patients with IgAN and HSPN are included, as 
we presume that the mechanisms for chronic disease progression in these different conditions 
should be the same with regard to the factors investigated in our project. 
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1.2.9 Treatment of IgAN/HSPN 
Initially, IgAN was regarded as a disease with a benign prognosis and the patients were often 
without treatment and were not regularly followed by a nephrologist. Since the middle of the 
1980s the prognosis of IgAN has been reported to be worse than had been previously believed. 
After studies in 1994 (140) demonstrating the renoprotective effect of angiotensin converting 
enzyme inhibitors (ACEIs) and then of angiotensin receptor blockers (ARBs) in 2000 (141), 
these therapeutic agents began to be applied as the cornerstone of the treatment of patients with 
IgAN. Patients with hypertension, proteinuria more than 1g/day and reduced GFR are at high 
risk of progression and should be treated to a target blood pressure of 125/75 mmHg and a target 
proteinuria of < 0,5 g/ day with ACEIs and/or ARBs (28, 34, 111, 139). It is likely that the risk of 
proteinuria is a continuum which should be an argument to also treat patients with lower grades 
of persistent albuminuria, which is not as clearly evidenced in the literature (111). Uncontrolled 
hypertension has an additive effect with proteinuria in driving progression of the disease (120, 
121). 
There is no international consensus on the indications and dosages of immunosuppressives.  
The relative rareness of the disease and the slow progression rate are limiting factors to larger 
randomized controlled trials (RTCs) with sufficient follow-up periods. In a recent meta-analysis 
it was concluded that steroid therapy reduces proteinuria and the risk of ESRD (142).  
Present recommendations are to add treatment with corticosteroids in patients with GFR > 30 – 
50 ml/min/1.73m² when the level of proteinuria remains higher than 1 g/day or if the GFR 
declines by more than 30% during 3 – 6 months observation, despite optimal treatment with 
blockers of the renin-angiotensin-aldosterone system (RAAS) and optimal blood pressure control 
(139). Patients with lower GFR should receive immunosuppressive treatment only in the event of 
rapidly progressive glomerulonephritis due to extensive crescent formation. In these patients, 
cyclophosphamide should be used in combination with corticosteroids in the same way as in 
patients with other forms of crescentic glomerulonephritis, a recommendation that is mainly 
based on experience from case series (143). The optimal treatment in the presence of less than 
50% crescents remains to be evaluated. Adequate supportive therapy may, to some extent, lead to 
the resolution of crescents (139). Patients with IgAN and coincident minimal change disease 
usually respond well to corticosteroid therapy (144).  
Side-effects may be reduced by targeted corticosteroid treatment at the sites of mucosal B- cell 
induction which in a recent pilot study led to a significant reduction in urinary albumin excretion 
(145). Effectiveness with regard to renal outcome has to be proven by larger studies. 
The evidence for the use of mycophenolate mofetil is still unclear and there may be racial 
differences in the response to this treatment (146). Azathioprine has not been shown to have any 
benefit for renal protection (147). 
The STOP-IgAN trial, initiated by Floege and Eitner, will hopefully provide an answer to the 
question on risks and benefits associated with the addition of corticosteroids and 
cyclophosphamide to optimized supportive treatment. In this large German multicenter 
randomized controlled trial, optimized supportive therapy includes blood pressure control by 
ACEIs and/or ARBs, the use of statins and the reduction of dietary salt and protein intake.  
 
Fish oil has beneficial anti-inflammatory and rheologic effects. It is safe and frequently 
prescribed in IgAN. However, according to a meta-analysis of available clinical studies the role 
of fish oil in renal protection is still inconclusive (148). 
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Tonsillectomy is widely applied in Japan in patients with IgAN but usually in combination with 
corticosteroids and its independent therapeutic efficacy has still to be proven (149-151). In 
European countries, tonsillectomy is currently only considered when there is a clear temporal 
relationship between tonsillitis episodes and relapses of macrohematuria or in the presence of 
other surgical indications. In a small Japanese study, tonsillectomy reduced proteinuria in 
transplanted patients with recurrent IgAN (152). 
 
The risk of recurrent IgAN after kidney transplantation is not influenced by the immuno-
suppressive regimen used, except for a protective effect of induction therapy with anti-thymocyte 
globulin, possibly related to augmented production of regulatory T cells (115, 153, 154). No 
specific therapy for recurrent IgAN is currently available.  
 
Sufficient-sized studies on the treatment of Henoch-Schönlein purpura nephritis in adults are 
scanty and most data are retrieved from retrospective studies in adults and from experiences in 
children (155-161). Risk factors for progression were the same as for IgAN and a similar 
treatment approach is therefore recommended. 
 
 
1.3 THE ROLE OF OXIDATIVE STRESS IN ATHERO- AND NEPHROSCLEROSIS 
Markers of inflammation and oxidative stress have been shown to be significantly associated 
with cardiovascular disease and progression of renal disease and there is increasing evidence for 
a causative connection (162-167). Oxidative stress is an imbalance in naturally occurring cellular 
and molecular mechanisms with increased production of reactive oxygen species (ROS) and 
insufficient anti-oxidant ability of the cells. One of the mechanisms influencing how ROS 
contribute to cellular stress is the activation of Nuclear factor-kappa B (NFκB) that 
transcriptionally regulates genes involved in inflammation, immunity, cell proliferation, 
differentiation and apoptosis. The source of the increased amounts of oxidants in kidney disease 
can be both endogenous kidney cells and exogenous infiltrating cells (165, 167). 
 It has been suggested that activated monocytes play a pivotal role in the development of 
atherosclerosis. Monocyte activation by inflammatory molecules or microbes results in enhanced 
cell surface expression of adhesion molecules and cell infiltration of the vascular wall (162). 
Activation of monocytes also involves increased intracellular production of oxygen radicals 
which can be measured as monocyte respiratory burst. One of the effects of reactive oxygen 
metabolites in the circulation is the formation of oxidized low-density lipoprotein (ox-LDL), 
widely used as a marker of oxidative stress. Renal biopsies from patients with glomerular disease 
show accumulation of oxidized lipoproteins (168). In the kidney, perturbations of cellular 
oxidant handling promote cell apoptosis, senescence and fibrosis. 
 
 
1.4 HYPERLIPIDEMIA AND STATIN TREATMENT IN RENAL DISEASE 
Dyslipidemia in renal disease usually has the atherogenic profile of elevated low density 
lipoprotein (LDL), reduced high density lipoprotein (HDL) and high triglycerides (TGs). The 
loss of lipoprotein lipase due to increased glomerular permeability and the stimulation of hepatic 
lipoprotein synthesis secondary to albuminuria contribute to the hyperlipidemia in CKD.  
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Lipids may cause mesangial proliferation and bind to glycoaminoglycans in the glomerular 
basement membrane, increasing its permeability (169, 170). Filtrated LDL, especially in its 
oxidized form, is engulfed by foam cells, derived from macrophages, vascular smooth muscle 
cells and mesangial cells, which further contributes to the renal injury. (171). Numerous 
experimental and clinical studies have demonstrated that lipid derangements are an independent 
risk factor for the development of renal disease (126).  
LDL is usually not directly measured but derived from the Friedewald formula. This formula 
cannot be used in the case of more pronounced hypertriglyceridemia, which is a common feature 
in patients with advanced kidney disease (172). 
 
Apolipoproteins are critical in lipoprotein formation and clearance (173). ApoA-I and A-II are 
the major structural proteins of HDL particles (174). ApoB-100 is the major protein of all other 
lipoprotein particles including very low-density lipoprotein (VLDL), intermediate-density 
lipoprotein (IDL), low-density lipoprotein (LDL) and lipoprotein a [Lp(a)] particles, thus 
reflecting the total number of these lipids. (175). Circulating VLDL particles are packed with 
triglycerides (TG) that are synthesized in the liver from endogenous fatty acids or dietary 
carbohydrates (176). VLDL particles with elevated TG are metabolized to small, dense LDL 
particles which are more atherogenic than normal size LDL particles (177). ApoB is considered 
to reflect the total number of potential atherogenic lipoprotein particles in plasma and it has been 
proposed that apoA-I corresponds to the level of potentially anti-atherogenic lipoproteins (178-
180). Several studies have shown that the apoB/apoA-I ratio is superior in predicting 
cardiovascular outcome compared to total cholesterol levels, LDL-cholesterol, total/HDL- 
cholesterol ratio or triglycerides (179-186). Higher ApoB and lower ApoA-I values are 
frequently observed in CKD (187, 188).  
 
A meta-analysis of 13 small studies in patients with renal disease demonstrated that the rate of 
decline in eGFR was lower in patients treated with statins than in those without this treatment 
(189). Statins exert immunomodulatory effects and may slow the progression of CKD by 
improving lipid profiles as well as by affecting inflammatory cell-signalling pathways (190, 
191). Statins also protect against the oxidation of LDL (192). The anti-oxidant effects of statins 
enhance endothelial function and support normal vascular activity (193, 194). Furthermore, 
statins inhibit the activation of mesangial cells by ox-LDL and high glucose and may alter the 
inflammatory renal response to cytokines which may be augmented by dyslipidemia (195, 196). 
 
 
1.5 T-LYMPHOCYTES IN IGAN 
The systemic as well as the mucosal production of IgA appears to be controlled by T 
lymphocytes (197, 198). CD4 T lymphocytes (T helper cells, Th cells) play a critical role in the 
adaptive immune response and promote antibody production and class switching in B cells (199). 
Th cells can be divided into four main lineages, Th1, Th2, Th17 and Treg, characterized by the 
different main signature cytokines, Interferon gamma (IFNγ), interleukin-4 (IL-4), IL-17 and 
TGFβ, respectively.  
IgAN has been described as a primarily Th2-dependent disease, although the pattern of 
peripheral T lymphocyte population, renal cytokine expression and phenotyping of intrarenal T-
cells subsets in IgAN suggests that both Th1 and Th2 may be involved (200-204). 
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Interleukin-2 (IL-2) is produced by activated T cells and plays a pivotal role in the proliferation 
of T lymphocytes after antigenic stimulation. Upon activation, the T cell expresses high-affinity 
receptors for IL-2 (IL-2R), and subsequently, a soluble form of the IL-2R protein (sIL-2R, 45 
kDa) is released. The release of sIl-2R appears to be a characteristic marker of continuous T 
lymphocyte activation and is attributed to playing a regulatory function during normal and 
abnormal cell growth and differentiation (205, 206). Previous experimental investigations and 
relatively small cross-sectional studies have demonstrated high production of IL-2 and IL-2R in 
IgAN (207-209). However, whether these factors are suitable as prognostic markers has not been 
validated in longitudinal studies. 
 
 
1.6 KIDNEY-BONE AXIS AND THE ROLE OF FGF23 
Fibroblast Growth Factor-23 (FGF23) is considered as a key player in chronic kidney disease-
mineral and bone disorder (CKD-MBD), a syndrome defined by increased mortality, vascular 
calcification, fractures and biochemical abnormalities. FGF23 is a circulating hormone that 
promotes renal phosphate excretion and reduces the synthesis of active 1,25-dihydroxy vitamin 
D3 by direct actions on the kidney (210, 211). In CKD, renal excretion of phosphate is 
compromised, leading to a compensatory rise in FGF23 level and development of secondary 
hyperparathyroidism (212, 213). Mild increments in FGF23 are commonly detected in CKD 2 - 
3, whereas its circulatory levels are markedly elevated in ESRD (214-216).  
High systemic levels of FGF23, both in CKD and in the general population, are linked to adverse 
outcomes including mortality and cardiovascular disease (CVD) (217-222). There is a debate 
ongoing as to whether FGF23 per se is detrimental to the cardiovascular system, or if FGF23 is 
merely a biomarker of multiple biochemical and metabolic derangements that parallel the 
progression of CKD. Recent experimental data favor the direct pathophysiological role of the 
FGF23 co-receptor Klotho in renal fibrosis and vascular calcification (223, 224), potentially 
explaining its relationship with CKD progression and CVD.  
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1.7 OBJECTIVES OF THE STUDIES 
The overall aim of this thesis was to gain greater knowledge about mechanisms of renal disease 
progression in patients with a uniform diagnosis of chronic inflammatory kidney disease. We 
chose to study patients with IgAN as this is the most common form of glomerulonephritis in 
developed countries with a high percentage of relatively young individuals at risk of end stage 
renal disease and premature cardiovascular morbidity and mortality.  
 
The specific objectives were to: 
 
- Investigate peripheral blood monocytes as a source of oxygen radicals in chronic kidney 
disease and the in vivo effect of atorvastatin-treatment on this variable (Study I).  
 
 
- Evaluate the apolipoprotein B/apolipoprotein A-I ratio, shown to predict cardiovascular 
disease, as a potential risk marker for severe renal outcome (Study II). 
 
 
- Investigate the impact of increased T-lymphocyte activation, assessed by soluble 
Interleukin-2 receptor alpha levels, on renal disease progression and how it correlates to 
histopathological findings (Study III). 
 
 
- Investigate fibroblast growth factor 23 (FGF23), a regulator of mineral metabolism, as a 
risk marker for renal disease progression in IgAN and its correlation to albuminuria 
(Study IV). 
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2 METHODS 
2.1 IGAN/HSPN PATIENT COHORT  
The patient population, that the four studies were based on, comprised all prevalent and incident 
adult patients with a renal biopsy-confirmed diagnosis of IgAN (with and without manifestations 
of HSP) who had been treated at the Departments of Nephrology at Karolinska University 
Hospital Solna between November 1994 and March 2009 and Danderyd University Hospital 
between February 2006 and May 2007 in Stockholm, Sweden (229 patients). The indication to 
perform a renal biopsy was the persistence of clinical symptoms suspicious of 
glomerulonephritis. Most of the patients had both hematuria and proteinuria with a proteinuria 
level greater than 0.5 g/ day but there were also 36 cases with less proteinuria on the date of renal 
biopsy, without ACEI/ARB treatment. Kidney biopsy is normally not performed at our 
department on patients presenting with isolated hematuria.  
New patients included in the follow-up study at Karolinska University Hospital Solna after 
March 2009 and until September 2011 (n = 33) are integrated in the analyses described in the 
„Additional Results‟ section. Only three patients declined to participate in the study. 
As a rule, the patients had been followed at the outpatient clinics after the renal biopsy, 
irrespective of the severity of the renal disease. Of the 242 patients at Karolinska University 
Hospital Solna, included between 1994 and 2011, 27 patients (11%) were lost to follow-up as 
they had been referred to a general practitioner, moved away from the district or failed to come 
to the clinical visits. In one patient, follow-up was stopped after more than 10 years of complete 
remission. Thirty-one patients developed CKD stage 5 (13%) and 6 patients died (2%). Five 
patients were excluded during follow-up as they developed malignancies. 
Figure 5 shows the annual number of incident and prevalent patients included in the project at 
Karolinska University Hospital Solna. On average, 13 patients per year have been included.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5: Number of patients included in the 
IgAN project by year at Karolinska 
University Hospital 
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The following clinical data are recorded in this project: 
 
 Date (and age) of onset, diagnosis, follow-up evaluation  
 Gender 
 Ethnicity 
 Inheritance (for IgAN, renal disease in general and ESRD, HT, cardiovascular 
disease, diabetes, rheumatologic disease) 
 Concomitant disease/ smoking 
 Disease manifestations at onset and reason for consultation 
 Renal biopsy reports 
 Debut of CKD stage 3 and 5,  ≥50 % decrease of eGFR, start of RRT 
 Debut of hypertension, CVD manifestations, date and cause of death 
 Weight and height 
 Medication at diagnosis, inclusion, follow-up visits 
 History of tonsillectomy 
 Annual blood pressure 
 Annual routine laboratory results  
 
 
In the studies presented in this thesis, we excluded patients with a concomitant diagnosis of 
malignancy (n = 2), diabetes (n = 7), inflammatory bowel disease (n = 1), rheumatoid arthritis (n 
= 4), severe ANCA negative systemic vasculitis (n = 1), antiphospholipid syndrome (n = 1), 
traumatic damage to the kidney (n = 1), nephropathia epidemica (n = 1) acute tubular necrosis (n 
= 2) or pregnancy (n = 1) or if they were ≥ 75 years old at the time of renal biopsy (n = 2). None 
of the patients had any liver disease or had started renal replacement therapy at baseline.  
 
For follow-up analysis, only patients with an observation period of at least 1 year were included. 
In study II, only patients with a renal biopsy performed at Karolinska University Hospital Solna 
after 1992 were included and the patients had been followed until November 2006.  
Study III and IV also included patients who had been diagnosed by renal biopsy before 1992 
and patients who had been diagnosed at another Swedish nephrology unit and referred to our 
department due to movement to our district. The inclusion period was extended to March 2009 
and patients had been followed until October 2010 (study III) or until May 2011 (study IV) 
respectively. 
The subgroups of patients included in the different studies are described in the results sections for 
each study and are summarized in table 2.  
 
 
2.2 HEALTHY CONTROL SUBJECTS  
Eighty-four control subjects from a population-based cohort were obtained from the Swedish 
population register and were matched to the patient group in study II and III by gender and age. 
These individuals had been selected by exclusion of a diagnosis of renal disease, malignancy, 
diabetes mellitus, liver disease or chronic rheumatologic or inflammatory disease through the 
National patient register.  
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 Table 2: Short summary of studies I – IV 
 
 Aim Number of 
study 
subjects 
Inclusion 
criteria 
Study design Laboratory 
methods 
Statistical 
analysis 
I Monocyte 
respiratory 
burst and effect 
of atorvastatin 
in IgAN 
16 patients 
(16 controls 
in 
experimental 
study) 
eGFR >20 ml 
/min/1.73m² 
not previously 
statin treated  
 
Clinical trial 
and 
experimental 
study 
FACS 
ELISA 
Routine 
biochemical 
analyses 
Descriptive, 
ANOVA 
II Impact of 
apoB/ apo A-I 
on renal 
outcome in 
IgAN 
70 patients 
70 matched 
controls 
CKD stages  
1-3  
Cross-
sectional and 
prospective 
cohort study 
Routine 
biochemical 
analyses 
Descriptive, 
Kaplan-Meier 
estimates, Cox 
regression 
models 
III sIL-2Ra as a 
predictor of 
renal outcome 
in IgAN 
194 patients 
84 matched 
controls 
(179 patients 
in follow-up 
analysis) 
CKD stages 1-
5, (for follow-
up study CKD 
stages 1-4) 
Not steroid-
treated within 
6 months 
Cross-
sectional and 
prospective 
cohort study 
Luminex 
Routine 
biochemical 
analyses 
Histo –
pathologic 
examination 
Descriptive, 
Linear 
regression, 
Kaplan-Meier 
estimates, Cox 
regression 
models 
IV Relationship of 
FGF23 to 
albuminuria 
and renal 
outcome in 
IgAN 
180 patients CKD stages  
1-4 
Prospective 
cohort study 
ELISA 
Routine 
biochemical 
analyses 
Histo-
pathology 
Descriptive, 
Linear 
regression, 
Kaplan-Meier 
estimates, Cox 
regression  
 
 
Ethical approval 
All studies were approved by the local ethics committee at the Karolinska University Hospital 
and, after 2004, the regional ethical review board, Stockholm, Sweden. Informed consent was 
obtained from all participants. 
 
2.3 BLOOD SAMPLE AND CLINICAL DATA COLLECTION 
At baseline, plasma and serum samples were spun and stored at -70° C. Clinical data and routine 
laboratory results were collected from the patients‟ records at the time of inclusion and once 
yearly thereafter. The healthy controls were asked to fill in a health questionnaire and a blood 
pressure test was performed in the sitting position after 5 minutes of rest.   
 
2.4 ROUTINE LABORATORY AND CLINICAL MEASUREMENTS 
Analyses of serum creatinine (reference < 100 µmol/l for men, < 90 µmol/l for women) were 
performed using routine methods. To correct for the different method-related  reference values 
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during the period from January 1
st
 2001 until  March 1
st
 2005,  5µmol/l were subtracted from the 
s-creatinine values obtained for standardization to isotope dilution mass spectrometry (IDMS), 
according to recommendations from the local laboratory. Calcium levels were corrected for s-
albumin using the equation: albumin- corrected calcium = s-calcium + 0.02*(40 - s-albumin). 
For the assessment of albuminuria, patients had either provided a 24-hour urine sample or a 
morning urine sample for analysis of the urine-albumin/creatinine ratio (U-alb/cr, reference < 3.0 
mg/mmol). From the latter samples, 24-hour albuminuria was calculated using the Cockroft 
Gault formula in accordance with Fournier (225) (U-alb/ 24 h = U-alb/cr*((140-
age)*weight*1.77/ 1000)/1000 for men and U-alb/24h = U-alb/cr*((140-age)*weight*1.5/1000)/ 
1000 for women). From the healthy subjects, a urine sample was obtained for analysis of the U-
alb/cr ratio. U-alb/cr values of < 2 mg/mmol were defined as 1 mg/ mmol, for calculation of 
median values. Hematuria on dipstick was recorded in the range of 0 to 3+. Body mass index 
(BMI) was calculated by dividing a person‟s weight by the square of their height. Mean arterial 
blood pressure (MAP) was calculated as the sum of diastolic blood pressure and one third of the 
difference between systolic and diastolic blood pressure. GFR was estimated by the four 
parameter MDRD equation for s- creatinine values standardized to IDMS (226) and by the CKD-
EPI equation (227). 
 
2.5 FLOW CYTOMETRIC ANALYSIS 
Flow cytometri or FACS (fluorescence-activated cell sorting) is a measurement of cell 
characteristics by laser-scanning while the suspended cells flow through the instrument. The 
refracted light (due to lens-like properties of the cell) and the reflected light (off the internal 
surfaces) provide information on the cells´ size and granularity, making it possible to 
differentiate between different white blood cells. The leukocytes are presented in a two-
parameter scatter plot histogram by the computer output. Forward scatter (FSC), expressed on 
the y-axis, correlates to cell size and side scatter (SSC), expressed on the x-axis, correlates to 
the density of the cell, which depends on the number of cytoplasmic granules and membrane 
size. Fluochrome that reacts with components in the cell or fluochrome-marked antibodies can 
be used to increase the information about the cells. The fluochromes are excited by the laser 
and emit light of a different wavelength (i.e. color).  
 
Figure 6. Principles of cell separation by cytometry 
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In study I, monocytes were selected by cytometry and their hydrogen peroxide formation 
(respiratory burst) was measured and quantified as mean fluorescence intensity (MFI). The 
analysis was performed in unstimulated cells and after stimulation of the cells with N-
formylmethionyl leucyl phenylalanine (fMLP) or Phorbol-12-myristate-7-acetate (PMA), using 
the 2‟, 7‟-dichlorofluorescein diacetate (DCFH-DA) method. 
2.6 LUMINEX METHOD 
The analysis of plasma sIL-2Ra concentrations (study III) was performed on the Luminex-100 
system (Luminex Corporation) using Milliplex-kit (Millipore), according to the manufacturer‟s 
instructions. In short, microspheres are dyed to create distinct colors and coated with capture 
antibodies. The sample is added to the microspheres and the specific analyte will be captured. 
Fluorescent tagged detection antibody is added and a laser detects both the color of the 
microsphere and the tagged detection antibody. An advantage of this method is that only small 
sample amounts are needed. The lower detection limit was 3 pg/ml and a value of < 3 pg/ml was 
defined as 2 pg/ml for statistical analysis. 
 
2.7 ANALYSIS OF OTHER BIOMARKERS  
Enzyme-linked immunosorbent assays (ELISA, R&D Systems; Minneapolis, MN) for monocyte 
chemoattractant protein-1 (MCP-1) (minimal detectable dose, MDD, 5 pg/mL), serum 
intercellular adhesion molecule – 1 (sICAM-1) ( MDD 0.35 ng/mL) , tumor necrosis factor 
receptor I and II (TNFR I and II) (MDD 0.6 pg/mL), and neutrophil gelatinase-associated 
lipocalin/ matrix metalloproteinase-9 complex (NGAL/MMP-9) (MDD 0.013 ng/mL) were done 
according to the instructions from  the manufacturer. Oxidized LDL (ox-LDL) was analyzed by 
ELISA purchased from Mercodia AB (Uppsala, Sweden) (study I and Additional results). C-
terminal FGF23 levels were measured using a commercially available enzyme-linked 
immunosorbent assay (ELISA) (Immutopics, CA, USA). A radioimmunoassay (RIA) was used 
for the analysis of 25(OH) vitamin D (Immunodiagnostic-systems, Boldon, UK) (study IV). 
 
2.8 DEFINITION OF RENAL OUTCOME 
Disease progression was defined by different outcomes in the studies. Study II: entering ESRD 
(defined by CKD stage 5); study III: entering ESRD (CKD stage 5) or  50% reduction in eGFR 
or a 30% eGFR decline within 5 years of follow-up; study IV: entering ESRD (CKD stage 5) or 
 50% reduction in eGFR (endpoint 2A) and entering ESRD (CKD stage 5) or  25% reduction 
in eGFR within 10 years of follow-up (endpoint 2B). In studies III and IV, outcome was also 
defined by the annual decline in eGFR (eGFR slope) (III, IV) and by time-averaged albuminuria 
during follow-up (IV). 
A composite endpoint was used in studies III and IV to reduce the number of misclassified 
patients due to a limited follow-up period. 
In the „Additional results‟ section a new definition of endpoint was introduced, namely 
developing CKD stage 3b or higher (CKD stage 3b+) in accordance with the new KDIGO 
guidelines for stratification of CKD stages (eGFR < 45ml/min/ 1.73m²). The reasoning for this is 
discussed in the „Findings and Implications‟ section. 
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2.9 EVALUATION OF HISTOPATHOLOGICAL FINDINGS 
Only a few renal biopsies had both been performed close to baseline evaluation in the different 
studies and also been classified by the new Oxford-MEST classification. This classification is not 
applicable in patients with manifestations of HSP and biopsy specimens with less than eight non-
globally sclerosed glomeruli. Comparisons between the levels of potential biomarkers and renal 
histopathological findings could thus only be made in small subgroups of patients (studies III 
and IV).  
All available biopsy reports that were based on the Oxford-MEST classification were used in the 
analyses presented in the „Additional results‟ section. 
 
2.10 STATISTICS (I-IV) 
Descriptive statistics were used to characterize the study populations, presenting mean (± SD) for 
normally distributed and median (interquartile range) or median (range) for non-normally 
distributed values. Categorical variables were expressed as percentages. Spearman‟s rank 
correlation was used to analyze relationships between non-normally distributed values.  
For cross-sectional analysis, comparisons of continuous variables between two groups were 
assessed using Student‟s unpaired t-test or Mann-Whitney U-test as appropriate. Comparisons 
between three groups were made using ANOVA test. Differences in proportions in different 
groups were compared by the Fisher‟s exact test.   
Comparisons between repeated measurements in one group were made by Wilcoxon rank test. 
 
Survival analyses were made using the Kaplan-Meier survival curve and log rank test for 
categorical variables and the Cox proportional hazards model for continuous variables. “Renal 
survival” was determined from the baseline examination, and patients were censored when not 
reaching the defined endpoint. Hazard ratios (HRs) for progression to the endpoint were 
determined by using univariate and multivariate Cox regression analysis and presented as HR 
and 95% confident intervals (CI).  
 
Linear regression models were used to investigate the associations of biochemical and clinical 
variables. Risk ratios (RRs) and correlation coefficients (beta) were determined as RR (95% CI) 
or change per unit of the analyzed variable (95% CI) respectively. 
Linear regression and the principal of least squares were also used to assess the annual eGFR 
slope by fitting a straight line through the calculated follow-up eGFR values. 
 
Logistic regression was used to analyze the association of biochemical or clinical variables to a 
categorical outcome variable. 
 
The two-sided p-value < 0.05 was considered to be statistically significant. Statistical evaluation 
was made by statistical software, STATISTICA 9 (StatSoft, Tulsa, UK) and STATA version 12 
(Stata Corp, College station, TX, USA). 
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3 RESULTS AND DISCUSSION 
 
3.1 PAPER I 
Atorvastatin-induced modulation of monocyte respiratory burst in vivo in patients with 
IgA nephropathy: a chronic inflammatory kidney disease. 
 
Respiratory burst of PMA-stimulated monocytes, measured by flow cytometry, was higher in 16 
patients with IgAN (eGFR 48 ± 18 ml/min/1.73m
2
) as compared to in healthy controls. After 
treatment of the patients with atorvastatin 20 mg/day during one month, there was a significant 
reduction of unstimulated, fMLP- and PMA- stimulated monocyte respiratory burst compared to 
baseline values (Figure 7). We observed no significant changes in ox-LDL, high sensitive CRP 
(hsCRP), MCP-1, ICAM-1, TNFR II and NGAL/MMP-9 and the urine-albumin/ creatinine ratio. 
 
 
 
Figure 7. Monocyte respiratory burst in healthy control subjects and in 16 patients with IgAN before 
and after treatment with atorvastatin 20 mg/day during one month. 
Respiratory burst is expressed as mean fluorescence intensity (MFI). The p-value is the result of 
Mann-Whitney-U test and Wilcoxon rank test respectively; fMLP, N- formyl- methionyl- leucyl- 
phenylanine; PMA, Phorbol 12-myristase 13-acetate. 
 
 
Our results are in line with the study by Fortuno et al who found enhanced monocytic NADH 
oxidase-mediated superoxide anion production in response to PMA in patients with early stages 
of kidney disease (228). A metabolic hyperactivity of monocytes may contribute to the oxidative 
stress that has been linked to progressive renal disease as well as to the development of 
atherosclerosis. Circulating and filtrated proteins can be oxidized by ROS released from 
activated monocytes with the formation of advanced oxidation protein products (AOPP) (229). In 
IgAN, the level of AOPP was independently predictive of disease progression (230) . The AOPP 
level and the degree of Gd-IgA1 in combination correlated to proteinuria and the rate of renal 
function decline which indicates that oxidative stress may modulate the nephrotoxicity of 
aberrantly glycosylated IgA1 in IgAN (24, 231).   
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Statins block the synthesis of two isoprenoids that normally attach post-translationally to 
intracellular signaling proteins and the G-proteins (194). Through this pathway various statins 
have been shown to directly inhibit NADPH oxidase activity (192). This is supported by our 
findings that both fMLP-and PMA-stimulated respiratory burst of monocytes were inhibited by 
atorvastatin treatment, due to the fact that fMLP- stimulation is receptor-mediated whereas PMA 
directly acts intracellularly. Our study is small and should be confirmed by larger investigations 
but it is interesting as it shows an effect of atorvastatin on monocyte respiratory burst in vivo, 
supporting earlier in vitro findings in monocytes from healthy individuals (232, 233). Changes in 
the levels of ox-LDL after atorvastatin-treatment were of borderline significance in our study (p 
= 0.06) 
We could not find any effect of atorvastatin-treatment on other inflammatory markers as could be 
expected according to earlier investigations (126). Presumably, an effect on systemic 
inflammation may be both time- and dose-dependent (234, 235) and can have been attenuated in 
our study by the RAAS blocking medications used in the majority of the patients.  
 
 
3.2 PAPER II 
Impact of apolipoprotein B/ apolipoprotein A-I ratio on renal outcome in IgA nephropathy. 
 
The apoB/apoA-I ratio was significantly higher in 70 patients with IgAN and CKD stages 1 - 3 
as compared to that in 70 age and gender matched healthy subjects (p < 0.001). ApoB was 
significantly higher in patients with IgAN than in healthy controls (p < 0.001) but there was no 
significant difference in apoA-I concentration.  
Patients were followed over a period of up to 11 years (median 3.8 years). Threshold values for 
apolipoproteins were defined according to previously used and suggested values (236). Baseline 
apoB/apo A-I values greater than 0.9 for men and greater than 0.8 for women (= high 
apoB/apoA-I) were associated with the risk of developing ESRD (log rank test, p = 0.02, Figure 
8). This association was independent of baseline eGFR [RR 6.50 (CI 95%, 1.20–35.12), p = 
0.03] and independent of s-albumin [RR 5.63 (1.06-29.98), p = 0.04]. Seven patients had reached 
the endpoint, 5 belonging to the high apoB/apoA-I group. 
 
  
 
 
 
 
 
 
 
Figure 8: Survival rate curve for stable renal 
function in relation to the apoB/apoA-I ratio  
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The results of this prospective observational study show an increased risk of progression to 
ESRD in IgAN patients with a high apoB/apoA-I ratio which is a new finding. ApoB alone had 
borderline significance as a predictor for the renal outcome (p = 0.06).  
In the patient group and in healthy subjects, the apoB/apoA-I ratio correlated significantly with 
other metabolic parameters at baseline such as age, BMI, serum creatinine and MAP and it 
correlated with hsCRP. There was no significant correlation between apoB/apoA-I ratio and 
baseline albuminuria which was unexpected but may be explained by the relatively low degree of 
median albuminuria at baseline in the study population. Only four patients had albuminuria in the 
nephrotic range (>3 g/24 hours) and all of them had a high apoB/apoA-I ratio. Two of these 
patients had well maintained renal function at baseline, received Prednisolone- and ACEI/ARB- 
treatment and had stable renal function at last follow-up. The other two patients were already in 
CKD stage 3 at baseline and progressed to ESRD within 16 months.  
In accordance with earlier studies in patients with IgAN, eGFR, albuminuria and s-albumin at 
baseline, albuminuria at one year of follow-up and time-averaged MAP during follow-up were 
all significantly associated with more severe renal outcome (111, 237).  
 
We could not confirm any association between BMI and renal outcome as has been shown in an 
earlier study in Chinese IgAN patients (127) even when we, in a secondary analysis, used the 
same outcome definition, which differed from ours (data not shown). Notably, the Chinese 
patient cohort was larger and also included some patients with concomitant diabetes, who were 
excluded in our study. The association between baseline hsCRP and renal outcome in IgAN has 
previously been investigated with conflicting results as discussed by Kaartinen et al (237). In our 
study, hsCRP was not associated with severe disease progression. The hsCRP levels in the 
patients were relatively low and were not significantly different from the levels in healthy 
controls which might have influenced our results. 
 
 
3.3 PAPER III 
Soluble interleukin-2 receptor alfa predicts renal outcome in IgA nephropathy.  
 
Soluble IL2-Ra levels were significantly higher in 194 patients with IgAN (median age 39 years, 
70% men) than in 84 age- and gender-matched controls (p < 0.001).  One hundred seventy nine 
patients with CKD stages 1 – 4 at baseline were followed for up to 16 years (median 52 months, 
range 12 – 188). Soluble IL-2Ra levels in the upper third tertile predicted a severe renal outcome, 
defined as development of CKD stage 5, a 50% decline in GFR during the follow-up period or a 
30% GFR decline within 5 years of follow-up, even after adjustment for age and the main 
clinical risk factors: eGFR at baseline, time-averaged (TA) albuminuria and TA MAP during 
follow-up (RR 5.67 (2.17-14.84), p < 0.001). Age, BMI and MAP at baseline were not 
significantly associated with renal outcome. 
In the analysis presented in the paper we chose to stratify sIL-2Ra by tertiles due to its non-
normal distribution. Actually, sIL-2Ra was clearly log-normally distributed and we therefore, in 
a secondary analysis, also examined the association of natural log-transformed sIL-2Ra to renal 
outcome. As shown in table 3, log sIL-2Ra was a significant predictor of severe renal outcome 
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also after adjustment for the established risk factors baseline eGFR, TA albuminuria and TA 
MAP.  Further adjustment for age, which was not predictive in crude analysis, did not change the 
results. 
  
Table 3. Unadjusted and adjusted risk estimates by Cox´s proportional hazard models for progression 
to the combined endpoint in the follow-up IgAN patient cohort (n = 179) 
 
Variables HR 95% CI p 
Log sIL-2Ra, crude analysis 
- adjusted for eGFR
 a
 , TA albuminuria and TA MAP  
1.80 
1.79 
1.34 – 2.43 
1.25 – 2.57 
<0.001 
  0.002 
eGFR
 a
  0.57 0.47-0.69 <0.001 
Albuminuria at baseline  1.59 1.34-1.89 <0.001 
TA albuminuria 2.42 1.90-3.08 <0.001 
TA MAP  1.09 1.05-1.13 <0.001 
Albuminuria ,urine-albumin per 24 hours (g/d); TA, time-averaged during follow-up; MAP, mean arterial pressure 
(mmHg); 
a
 stratified by 10 ml/min/1.73m² 
 
According to the Oxford classification, the presence of more than 25% tubular atrophy/ 
interstitial fibrosis (T1-2) was associated with higher sIL-2Ra levels, after adjustment for s-
creatinine levels. Table 4 shows further associations found in the subgroup of patients with a 
renal biopsy classified by Oxford-MEST score and performed close to baseline analysis. 
 
Table 4. Summary of p- values for differences in laboratory results and clinical findings at baseline 
with respect to Oxford classification scores in renal biopsies performed within 4 months (n = 24) 
 
 
 
M0:M1 
(n= 20:4) 
E0:E1 
(n = 20:4) 
S0:S1 
(n=19:5) 
T0: T1-2 
(n=17:7) 
sIL-2Ra  0.35 0.16 1.00 0.013 
s- creatinine  0.35 0.18 0.33 0.003 
Degree of hematuria  0.029 0.029 0.16 0.15 
Albuminuria 0.157 0.210 0.044 0.099 
MAP 0.115 0.157 0.019 0.664 
BMI 0.682 0.494 0.230 0.153 
Time from onset to biopsy 0.682 0.737 0.891 0.034 
P-values (two sided) are results of Mann Whitney U- test, p < 0.05 in bold. sIL-2Ra, soluble Interleukin 2 receptor 
alfa; degree of haematuria on dipstick (0,1+,2+,3+); MAP, mean arterial pressure; BMI, body mass index.  
 
In the 265 patients included in the Oxford classification study, proliferative changes and 
segmental glomerulosclerosis were strongly associated with proteinuria at the time of biopsy. 
Segmental glomerulosclerosis also was associated with higher initial MAP as in our patient 
group. Tubulointerstitial changes were associated with a reduced initial eGFR, higher initial 
MAP and proteinuria. The correlation of the different factors included in the MEST-score with 
the degree of hematuria is not described in the original paper by Cattran et al or the validation 
studies of the Oxford classification referred to in this thesis (89, 96-98). 
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This is the first report of an association of sIL-2Ra levels with renal disease progression, 
independent of other well-established clinical risk factors. The findings of increased levels of 
sIL-2Ra in IgAN are in agreement with cross-sectional and experimental studies performed by 
other groups (207-209, 238). A disturbed mucosal immune response to environmental factors 
such as microbial or food antigens may lead to activation of the innate immune system, 
triggering of inflammatory transcription factors and the generation of mediators that activate the 
adaptive immune system constituted by T and B cells (46). T-cell activation also has been shown 
to contribute to the altered glycosylation of IgA1, which plays a predominant role in the 
pathogenesis of IgAN (30, 239-241). 
Moreover, infiltrating T lymphocytes in the peritubular space sustain interstitial inflammation 
thus further promoting the development of interstitial fibrosis and tubular atrophy as described in 
figure 4 (242-244). 
This study provides further support for the view that IgAN is a T-cell driven disease and that 
increased T-cell activation in progressive disease may be a suitable target of therapy. 
 
  
3.4 PAPER IV  
FGF23, albuminuria and disease progression in patients with chronic IgA nephropathy. 
 
FGF23 was measured at baseline in 180 patients with IgAN in CKD stages 1 – 4 and without any 
concomitant disease. FGF23 values (median 18.5 RU/mL, range 5.4 – 138.7 RU/mL) 
significantly correlated with albuminuria, serum albumin, eGFR, calcium, parathyroid hormone 
(PTH), MAP, BMI and the number of antihypertensive drugs used at baseline. There was no 
significant association between FGF23 and phosphate, 25-hydroxy-vitamin D (25(OH) vitamin 
D) or age. Patients who were treated with ACEIs and/or ARBs had higher FGF23 levels 
compared to those without this treatment. 
The patients had been followed for a median of 55 months (range 12 – 177 months). Time-
averaged albuminuria during follow-up was 0.18 g/24 hours (range 0 – 7.4 g/24 hours) and the 
annual loss of eGFR was 0.8 ml/min/1.73m² (range -8.4 to 32.3 ml/min/1.73m²). In multivariate 
regression models, log-transformed FGF23 levels at baseline correlated to time-averaged 
albuminuria and to the annual decline of eGFR during follow-up, independent of other metabolic 
factors and independent of baseline albuminuria, eGFR and the treatment with ACEIs or ARBs 
(tables 5a and b). 
 
Table 5.  Multivariate regression model predicting a) time-averaged albuminuria (g/24 hours) and  
                b) the annual loss of eGFR (ml/min/1.73m²)  
a) 
Variable Change in time-averaged 
albuminuria 
P for Trend 
per increase in log FGF23 (RU/ml) 0.26 (0.05 - 0.47) 0.02 
per 10 ml/min/1.73m² of eGFR -0.05 (-0.10 to -0.005) 0.03 
per 0.1 mmol/L of calcium -0.24 (-0.35 to -0.13) <0.001 
per 1 g/24 hours of albuminuria 0.45 (0.34 - 0.57) <0.001 
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b) 
Variable Change in annual eGFR loss P for trend 
per increase in log FGF23 (RU/ml) 1.50 (0.40 - 2.60) 0.008 
per 0.1 mmol/L of calcium -1.04 (-1.66 to -0.41) 0.001 
per 1 g/24 hours of albuminuria 1.46 (0.85 - 2.07) < 0.001 
 
In a stepwise regression model log FGF23, age, gender, s-albumin, baseline albuminuria, baseline eGFR, calcium, 
phosphate, PTH, 25(OH) vitamin D, mean arterial pressure, body mass index and the use of ACEIs and/or ARBs 
were included. Log FGF23, calcium and albuminuria were retained as significant (adjusted R
2 
= 0.44, p < 0.001 for 
the whole model in a) and R² = 0.22, p < 0.001 for the whole model in b). The tables depict the regression 
coefficients (95% confidence interval) adjusted for the listed variables. FGF23, fibroblast growth factor 23; RU, 
relative units. 
 
 
For survival analysis, renal endpoints were defined as either A) entering ESRD (CKD stage 5) or 
≥ 50% reduction in eGFR or B) entering ESRD or ≥ 25% reduction in eGFR during 10 years. 
Using the MDRD eGFR equation, 15 patients (8%) were defined as progressors according to 
endpoint A and 34 patients (19%) reached endpoint B. Using the CKD-EPI eGFR equation a 
total of 17 patients (9%) reaching endpoint A and 39 patients (22%) reaching endpoint B were 
identified. LogFGF23 was significantly associated with renal outcome in all these models, 
independent of other markers of mineral metabolism and independent of eGFR and MAP or 
baseline albuminuria. When adjusted for all the factors included in the multivariable regression 
analysis described above, log FGF23 remained to be a predictor for outcome B, independent of 
whether eGFR was estimated by the MDRD or the CKD-EPI equation, but the association to 
endpoint A was no longer significant. 
 
Inspired by the prognosis model by Berthoux et al (120), we calculated a risk score that could be 
used during clinical follow-up, including the presence of hypertension, albuminuria ≥ 1g/day and 
FGF23 levels > 23 RU/mL. Ten of 22 patients with all three risk factors at baseline (45%) 
reached endpoint A (HR compared with 0-2 risk factors: 20.53 (6.43 – 65.54), p < 0.001) and 15 
of these 22 patients (68%) reached endpoint B (HR compared with 0-2 risk factors: 9.71 (4.86 – 
19.40), p < 0.001).  
 
In summary, we report on novel associations between FGF23 and albuminuria across the 
spectrum of CKD stages 1 – 4 and a predictive value of baseline FGF23 levels for both the 
persistence of albuminuria during follow-up and for renal outcome in IgAN.  
The value of FGF23 as a potential biomarker for cardiovascular pathology has been supported by 
a number of recent studies where FGF23 was associated with endothelial dysfunction, 
atherosclerosis and left ventricular hypertrophy (217, 218, 221, 245). An association with renal 
disease progression has earlier been found in a heterogenous CKD population (246) and in 
transplant recipients (247) but not in patients with a single underlying renal diagnosis. It is 
assumed that FGF23 may reflect the over-all risk exposure to the factors that determine its 
expression, including hyperphosphatemia, dietary phosphate load, the degree of secondary 
hyperparathyreoidism, vitamin D levels, a decrease in its cofactor Klotho and RAAS activation. 
At higher concentrations, FGF23 may also exert non-specific and Klotho-independent effects 
 30 
(248, 249) which could directly contribute to glomerular damage, despite the localization of 
Klotho being restricted to the tubuli. This has still to be proven. Alternatively, FGF23 levels 
might reflect the vascular status that secondarily aggravates a decline in renal function and/or 
proteinuria.  
In our study, we did not find any association of vitamin D levels with albuminuria or renal 
disease progression which could have been suggested by experimental studies showing that 
vitamin D treatment can suppress the RAAS and other pathological mechanisms involved in the 
progression of proteinuric renal disease (250-252). Treatment modalities in our study, with the 
majority of patients treated with ACEIs or ARBs at baseline and 3% on calcitriol 
supplementation, may have influenced our results. 
Phosphate levels were predictive of renal disease progression to either of the endpoints in crude 
analysis but not in multivariable models. 
 
 
3.5 ADDITIONAL RESULTS 
3.5.1 Soluble TNF receptors, albuminuria and renal outcome 
TNFα is produced by a variety of cells, including monocytes, macrophages, adipocytes, B- cells, 
T-cells, dendritic cells and mast cells. As a central mediator, it is involved in the innate and 
adaptive immune responses. TNFα exerts its actions through two structurally distinct receptors, 
TNFR I and II, found on nearly all cell surfaces, and induces the expression of adhesion 
molecules, chemokines and apoptosis in susceptible cells (253, 254). Both receptors are shed into 
the circulation as a response to inflammatory signals. Soluble TNFRs are more easily measured 
than TNFα since they occur in the circulation at 100 –1000 times higher concentrations. The role 
of sTNFRs can be that of natural antagonists, neutralizing the effect of TNFα, or that of ligand 
passers that keep TNFα in a circulating reservoir, thus protecting it from degradation and, over 
time, possibly enhancing its effects. In experimental models, TNFα causes direct glomerular 
injury (255, 256) and in diabetic patients, TNFα levels have been associated with the severity of 
proteinuria (257). TNFα levels in the supernatant from peripheral blood lymphocytes were higher 
in patients with IgAN than in healthy controls (258). It has also been shown that polymeric IgA 
stimulates mesangial TNFα production (259) and that mesangial derived TNFα in IgAN is a 
mediator for the mesangial-tubular and mesangial-podocytic communication (65, 260). 
Moreover, increased TNFα levels have been associated with cardiovascular risk (261) and are 
known to influence lipid metabolism (262). In 43 patients from our study population, examined 
within 6 months of renal biopsy, (eGFR 56 ± 26 ml/min/1.73m²) we had earlier found a close 
linear correlation between levels of soluble tumor necrosis factor receptors I and II (TNFR I and 
II) and renal function with a correlation coefficient as high as r = 0.94, p < 0.001 for sTNFRI vs 
creatinine and r = 0.89, p < 0.001 for sTNFR II vs creatinine (presented as a poster at 11
th
 
International Symposium on IgAN in Tokyo 2006) which is even higher than the associations 
found in other CKD patient cohorts (263, 264).  
 
We now repeated the measurement of TNFR levels in the 179 patients included in the follow-up 
analysis in study III. Similar to s- creatinine and sIL2-Ra, the levels of sTNFR I and II showed a 
log-normal distribution whereas baseline eGFR was normally distributed. Figure 9 shows a 
strong linear correlation of log TNFRI and II to baseline eGFR (r = -0.73, p < 0.001 and r =         
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-0.66, p < 0.001 respectively). The correlation of log sIL-2Ra to baseline eGFR was also 
significant but weaker (r = -0.22, p = 0.003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In multivariable regression analysis, adjusted for age, baseline eGFR, BMI, MAP and the use of 
ACEIs or ARBs, logTNFR I and log TNFR II independently correlated to baseline albuminuria 
[Regression coefficient for change in albuminuria (g/24 hours) per increase in log TNFRI:  
β = 1.03 (0.56 – 1.50), p < 0.001 and per increase in logTNFRII : β = 1.06 (0.55 – 1.57), p < 
0.001)]  
Log TNFR I and II also correlated to logIL-2Ra and the association was independent of baseline 
eGFR and baseline albuminuria [Regression coefficient for change in log IL-2Ra per increase 
in logTNFR I: β = 2.08 (1.23 – 2.93), p < 0.001 and per increase in logTNFR II: β = 2.11 
(1.18 – 3.04), p < 0.001]. 
 
Figure 9. Correlation 
of  logTNFR I and 
logTNFR II  to 
baseline eGFR 
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In survival analysis, baseline logTNFR I and logTNFR II, similar to logIL-2Ra, were 
significantly associated with the combined renal endpoint as defined in paper III, after 
adjustments for baseline eGFR, TA albuminuria and TA MAP (Table 6). 
 
 
Table 6. Risk estimates by Cox’s proportional hazard models for progression to the combined renal 
endpoint, adjusted for baseline eGFR, TA albuminuria and TA MAP. 
 
Variables HR 95% CI P 
Log TNFR I (ng/mL) 8.37  1.83 – 38.30 0.006 
Log TNFR II (ng/mL) 42.03 7.09 – 249.16 < 0.001 
 
The correlation of log-transformed TNFR levels to eGFR in our study population was in 
concordance with the findings in heterogenous CKD patient cohorts (263, 265, 266) and in type 
2 diabetic patients without proteinuria (267). In the latter study, diabetic patients with both TNFR 
I and TNFR II levels above median values (defined as high level) had a greater decline in renal 
function compared to those with a high level of only one receptor or a low level of both 
receptors.  
 
The predictive value of TNFR I and II for renal outcome in IgAN, independent of other strong 
progression risk factors is a new finding. This is in line with the hypothesis that plasma TNFR 
levels in patients with IgAN, and possibly also in patients with CKD due to other causes, not 
only are elevated due to retention when the glomerular filtration ratio falls but may also reflect an 
„inflamed‟ state that increases in lower CKD stages and further promotes renal disease 
progression. In a post hoc analysis of the CARE study (268), patients with sTNFR II levels in the 
upper tertile, similar to patients with CRP levels in the upper tertile, had a more rapid renal 
function loss compared to those with sTNFR II- or CRP levels in the lowest tertiles.  
Interestingly, despite pravastatin-treatment not being associated to renal function loss in the 
whole study cohort, subjects with both CRP and sTNFR II in the highest tertile appeared to 
derive more renal benefit from pravastatin than those without. In these „inflamed‟ patients the 
renal function loss in patients receiving pravastatin was 0.8 mL/min/1.73 m² slower than in those 
receiving placebo (269). 
 
 
3.5.2 Patients with IgAN and HSPN at one single center  
The initial reasons for consultation of a doctor in the 242 patients who have been treated at 
Karolinska University Hospital Solna represented common clinical presentations of IgAN as 
shown in figure 10. All patients with renal findings of IgAN who had typical skin manifestations 
of HSP were defined as having HSPN. Immunofluorescence staining of skin biopsies for the 
detection of IgA deposits was not routinely performed. Similarities and differences in hereditary 
and clinical parameters between patients with IgAN and patients with HSPN, according to this 
definition, are presented in table 7.  
Ten patients in the IgAN group had malignant hypertension at presentation. 
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Figure 10. Reasons for consultation in 242 patients at Karolinska University Hospital Solna.  
 
 
Table 7. Demographics of 222 patients with IgAN without and with manifestations of HSP (= 
HSPN) (17 IgAN patients and 3 HSPN patients excluded due to concomitant disease)  
 
Characteristics IgAN HSPN p- value 
No of patients N = 188 N = 34  
Female 30% 41% 0.23 
Caucasian 94% 94%  
Biopsy at Karolinska 87% 91%  
Child at onset / at diagnosis 17% / 7% 21% / 9% 0.72 
Time from onset to diagnosis (months) 1.3 (0 - 36) 0.4 (0 – 24) 0.03 
Age at diagnosis (years) 33 (9 – 77) 38 (11 – 78) 0.08 
Family history of renal disease
a 
/ ESRD 
Family history of HT 
16% / 4% 
    39% 
12% / 6% 
    35% 
0.61 / 0.39 
    0.54 
Follow-up from diagnosis  (years) 6.3 (0 - 36.7) 5.9 (0 – 15.6) 0.58 
Treated with corticosteroids /  + Cyclophosphamide 13% / 0.5% 56% / 12% < 0.001 
Treatment at last follow-up 
- ACEI/ARB 
- Statin 
- Fish oil 
- Vitamin D 
 
78% 
23% 
13% 
19% 
 
50% 
21% 
6% 
6% 
 
0.003 
1.0 
0.38 
0.12 
Tonsillectomy   4%   6% 0.65 
Developed hypertension /CVD       73% / 5% 65% / 9% 0.39/ 0.40 
Developed ESRD (CKD stage 5) 
Developed CKD stage 3b+  
Developed CKD  stage 3b+ before age 45 
14% 
33% 
N = 50/62 (81%) 
  9% 
15% 
N = 4/5 (80%) 
0.59 
0.08 
 
Albuminuria at last FU < 0.2g/day 63% 79% 0.09 
 Death     2% 3%  
 a Three percent of IgAN patients and none of  HSPN patients  had a family history of  biopsy-confirmed IgAN/HSPN. 
Numeric values are median (range); p-values were calculated by Fishers‟ exact t-test or Mann-Whitney-U test 
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For this analysis, patients had been excluded in the presence of concomitant diseases of either 
diabetes (n = 7), malignancy (n = 2), chronic rheumatologic (n = 5) or chronic inflammatory 
bowel disease (n = 2), traumatic damage to the kidney (n = 1), acute tubular necrosis in 
hypersensitivity reaction to an antibiotic (n = 1), nephropatia epidemica (n = 1) or organ damage 
secondary to alcoholism (n = 1). An additional endpoint was defined as CKD stage 3b+ (eGFR < 
45ml/min/1.73m²) and we found that more than 80% of the patients who had developed CKD 
stage 3b+ reached this endpoint before the age of 45 which implies a high risk of the need of 
RRT during working age and also an enhanced risk of premature cardiovascular disease. 
 
Comparing patients with IgAN with and without manifestations of HSP, there were no 
significant differences in sex, onset or diagnosis in childhood, family history of renal disease/ 
ESRD, the percentage of patients that had developed hypertension at onset or during follow-up 
or the percentage of patients that had developed ESRD.  
On the other hand, patients with HSPN had been diagnosed earlier after the onset of clinical 
symptoms and had received immunosuppressive treatment to a higher extent. Patients with 
HSPN were to a lesser degree on treatment with ACEIs/ARBs at last follow-up which might be 
explained by the fact that more patients with HSPN compared to patients with IgAN tended to be 
in clinical remission with regard to albuminuria at that time. Also there was a trend towards 
fewer patients with HSPN, compared to patients with IgAN, developing CKD stage 3b+. Thirty-
nine percent of the IgAN patients who developed CKD stage 3b+ had been diagnosed before 
1998 when the current recommendations for treatment with ACEIs/ ARBs and 
immunosuppressives had not yet been established.  
The discrimination between IgAN and HSPN is complicated by the fact that some patients may 
have a clinical picture of HSPN in childhood which with progressing age acquires all the features 
of chronic IgAN. This was also the case in the patient population presented here. 
 
 
3.5.3 Can we predict renal outcome in individual patients?   
Clinical data at time of diagnosis have been used in most of the proposed prognostic models for 
renal outcome in IgAN (120, 270-273). Few of them have been validated in independent patient 
cohorts and they have not been widely adopted.  
The scoring system for ESRD risk prediction in groups of patients, developed by Goto et al 
includes, apart from generally applied variables, the aspect of a possible increased risk of 
hereditary CKD and the degree of hematuria (273). This prognostic model was shown to be 
applicable to predict the 10-year risk of ESRD in a nation-wide unselected cohort of Norwegian 
IgAN patients and predicted also which patients had the highest risk of developing ESRD after 
10 – 20 years of follow-up as well as all-cause mortality risk (274). Disadvantages with this 
scoring system are: the complexity of variables included, posing a problem with missing data, 
and that it was not based on the new Oxford-classification of histopathological findings.  
The simpler Absolut Renal Risk (ARR) score, presented by Berthoux et al (120) allows for the 
increased mortality risk in CKD patients by predicting the 10- and 20-year cumulative incidence 
of dialysis or death, similar to the Framingham risk score for cardiovascular events and death. 
The score is derived by counting the risk factors (1) arterial hypertension, (2) proteinuria ≥ 1 g/ 
day and (3) severe pathologic lesions [global optical score, GOS ≥ 8, according to their French 
scoring system as presented in 1990 (83, 275)]. The authors analyzed a prospectively established 
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database of 332 locoregional IgAN patients, optimally treated to achieve a blood pressure (BP) 
target of ≤ 130/80 mmHg and to reduce proteinuria below 1 g/day. Importantly, they could 
demonstrate an improvement in the survival of patients with BP at target. They also showed that 
the survival curves for patients that achieved reduction of proteinuria were similar to those with 
no or low proteinuria at baseline. Control of hypertension and proteinuria had additive effects on 
survival. The substitution of GOS ≥ 8 by Oxford-MEST score of 3 to 5 was proposed in order to 
adapt this ARR score to the new Oxford classification. 
 
To evaluate the predictive value of the adapted ARR score in our patient population, we analyzed 
clinical data from 72 IgAN patients, in whom the renal biopsy had been scored according to the 
Oxford-MEST classification for inclusion of the patients in the ongoing European multicenter 
VALIGA study (Validation of the Oxford Classification of IgA nephropathy). The patients had 
been followed for a median of 80 months (30 – 226 months). 
Patients with an ARR score of 3 versus those with an ARR score of 0 – 2 had significantly 
increased risk of ESRD [HR 15.64 (95% CI 2.98 – 82.04), p = 0.001]. The number of the 
patients in the different ARR risk groups is shown in figure 11. Seven patients reached ESRD 
(CKD stage 5) during follow-up with five patients belonging to the highest risk group. No patient 
had died. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Kaplan-Meier curve showing that ARR risk scores are associated with renal outcome 
For definition of “severe pathologic lesion” as one of the risk factors included in the ARR score, “global 
optical score ≥ 8” was substituted by “MEST ≥ 3” as proposed by Berthoux et al (120), using the new 
International Oxford classification instead of the local French scoring system. Other risk factors used for 
calculation of the ARR score are the presence of hypertension and of proteinuria ≥ 1 g/ day (here 
substituted by albuminuria ≥ 1 g/day) at diagnosis. 
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A different approach to the prediction of renal outcome is the formula developed by the Toronto 
group, presented by Bartosic et al (276). Instead of predicting outcome at diagnosis, they 
computed blood pressure (BP) and daily proteinuria during follow-up and found that, from these 
parameters, prediction of the yearly eGFR slope later in the disease course could be safely 
derived after three years of follow-up. 
 
 Toronto formula: ((TA proteinuria*(-0.13) + TA MAP*(-0.016) + 1.57))*12.  
 
This formula has been validated in a European patient cohort in which the actual rate of 
progression could be predicted within 4 ml/min/year in 75% of subjects, predicting patients with 
the most rapid deterioration with the greatest accuracy (277). 
 
To explore the applicability of the ARR score and the Toronto formula in some individual 
patients from our department we investigated clinical baseline and outcome variables in patients 
with IgAN and no concomitant disease that had been included in the VALIGA study. In this 
group, we compared the patients with the renal biopsy classified as M1E0S1T0 or M1E0S1T1 
respectively, according to the Oxford classification, thus differing only with regard to the 
presence or absence of ≥ 25% and < 50% of tubular atrophy/ interstitial fibrosis. This 
discriminating variable was chosen due to the high impact generally found for tubulointerstitial 
changes in risk predicting models. 
Figure 12 illustrates the clinical course in these patients with regard to the renal parameters s-
creatinine and albuminuria and with regard to blood pressure during follow-up. 
 
One patient in the M1E0S1T0 group (male age 18) experienced rapid renal function decline after 
an initially slow progression rate and a period of proteinuria remission that had occurred despite 
inadequate blood pressure control. There was also significant weight gain during the follow-up 
period from BMI 20 to 26. The other five patients had slow progressive or stable disease. None 
of these patients had received immunosuppressives. 
 
Two patients in the M1E0S1T1 group developed ESRD and four of seven patients in this group 
had an annual eGFR loss of at least 2 ml/min/1.73 m². Only „female age 42’ had been treated 
with immunosuppressives. She was put on an ACE inhibitor directly after the renal biopsy in 
1995 and a six-month course of oral Prednisolone was introduced after two years due to a 
doubling of s- creatinine. A repeated biopsy was performed in 1999, still showing active 
crescentic lesions, as well as advanced chronic lesions, and a new course of Prednisolone 
treatment was introduced which could however not prevent the progression to ESRD. 
Albuminuria and MAP during follow-up never reached current treatment goals.  
 
Tables 8 and 9 describe baseline and follow-up clinical characteristics of all the cases presented 
in the graphs. ARR score and predicted annual eGFR slope by the Toronto formula were 
calculated. We also applied our risk score, evaluated during follow-up as proposed in paper IV, 
including the parameters: hypertension, albuminuria ≥ 1g/day and FGF23 levels > 23 RU/mL 
(here called FGF23 risk score).  
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Figure 12 .Patients with IgAN and an Oxford- biopsy score of M1E0S1T0 or M1E0S1T1           
The cases are labeled with sex (m, male; f, female) and the age at the time of renal biopsy 
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Table 8: Patients with the renal biopsy scored as Oxford-M1E0S1T0 
 
 f age 23 m age 18 m age 27 m age 26 m age 55 f age 34 
       ACEI/ARB (% of time) 0%    100%  73% 100% 99% 0% 
No of aHTs at last FU 0 4 1 2 1 0 
Fam history of renal disease/HT  no / no no / yes no / yes yes / yes no / no no / no 
Year of onset/ biopsy ‟92 / ‟94 ‟92 / ‟96 ‟98 / ‟99 ‟89 / „00 ‟93 / „03 ‟05 / „06 
% crescents in biopsy 0% 9% 27% 0% 0% 0% 
BMI (biopsy – last FU) 22 - 24 20 - 26 24 - 24 26 - 26 26 - 26 19 - 19 
Remission of hematuria yes no no yes yes no 
Smoker  no no no no no no 
CKD stage at diagnosis 1 1 2 2 3a 1 
ARR score
1
 0 2 1 1 2 0 
FGF23 risk score
2
  0 3 0 1 3 0 
Time from biopsy to FGF23 
measurement (years) 
7 4 1 3 0 2 
 Predicted
3
/actual eGFR slope 3.0 / 0.5 -7.4 / -4.6 -0.9 / -0.7 0.3 / -1.4 -0.7 / -1.5 2.3 / 0.9 
Dialysis or Death / CKD stage 3b+ no / no yes / yes no / no no / no no / yes no / no 
 
 
Table 9: Patients with the renal biopsy scored as Oxford-M1E0S1T1 
 
 m age 18 m age 43 f age 42 m age 28 m age 35 m age 33 m age 52 
 ACEI/ARB (% of time) 93% 98% 99% 100% 98% 100% 100% 
No of aHTs last FU 1 1 4 2 2 1 5 
Fam history of renal disease/HT no / no yes / yes - no / - no / no no / no no / no 
Year of onset/ biopsy ‟94 / „95 ‟94 / „95 ‟95 / „95 ‟70 / „92 ‟99 / „00 ‟85 / ´03 ‟98 / „06 
% of crescents in biopsy 0% 0% 22% 0% 0% 0% 0% 
BMI (biopsy – last FU) 23 - 27 24 - 24 22 - 22 30 - 29 30 - 33 19 - 19 31 - 32 
Remission of hematuria no - - no yes yes no 
Smoker no no no no no no no 
CKD stage at baseline 2 3a 3a 3a 2 1 3a 
ARR score
1
 2 3 3 3 3 2 3 
FGF23 risk score
2
 2 3 3 1 2 1 3 
Time from biopsy to FGF23 
measurement (years) 
2 1 2 4 2 1 2 
Predicted
3
/ actual eGFR slope -2.0 / -2.1 -2.3 / -3.1 -6.5/-10.3 -2.6 / -1.6 0.0 /-2.1 -0,2 / -1.3 -5.7 /-6.0 
Dialysis or Death / CKD stage 3b no / yes yes / yes yes / yes no / yes no / no no / no no / yes 
 
1ARR, adapted: MEST ≥ 3, presence of hypertension, albuminuria ≥1 g/24h; 2presence of hypertension, , 
albuminuria ≥ 1 g/24h, FGF23 > 23 RU/ml; 3predicted by the Toronto formula (276); FU, follow-up; HT, 
hypertension; aHT, antihypertensives. Cases with ESRD or CKD stage 3b+ are presented in bold. 
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These examples illustrate the importance of continuous re-evaluation of an individual patients‟ 
risk profile during follow-up and the usefulness of currently available risk prediction models. 
Though not including histopathological findings, the Toronto formula as well as our proposed 
FGF23 risk score may to some extent mirror the pre-existing renal damage. 
The value of repeated eGFR measurements during the first years of follow-up in risk prediction 
has also been shown earlier by Rekola et al in a Swedish patient cohort (278). In this study, 50% 
of the patients with initial normal renal function and a negative eGFR slope of more than 1.1 
ml/min/1.73m²/year had subnormal renal function during follow-up.  
 
We could not use a combination of the biomarkers examined in the studies of this thesis for risk 
prediction analyses as these markers in the majority of patients had been analyzed in blood 
samples obtained at different time points during the follow-up period. Future studies will show 
which biomarkers explored world-wide are those that have the greatest contributory value in risk 
predicting models and clinical decision trees.  
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4 GENERAL DISCUSSION 
4.1 METHODOLOGICAL CONSIDERATIONS  
 
Study population and follow-up period 
IgAN is a relatively rare disease, which impedes the possibility to increase patient numbers and 
improve statistical power in studies like ours. Research on IgAN is further embarrassed by 
individual variability in disease manifestations, leading to a diagnosis in different CKD stages 
and little knowledge of the duration and progression rate from disease onset. Furthermore, in the 
majority of cases, IgAN progresses slowly, thereby necessitating a long follow-up period to 
correctly identify patients with severe renal outcome.  
The clinical characteristics of IgAN patients at Karolinska University Hospital are comparable to 
patient cohorts described from other European centers (120, 128, 155, 274, 277, 279). Some of 
the differences seen can be ascribed to the catchment area of the different hospitals, local policies 
for patient referral and the performance of a renal biopsy, treatment traditions and follow-up 
routines.  
Benefits of our study cohort are the high attendance of the patients participating in the study, the 
non-selective referral policy to our department by means of disease severity, and our possibility 
to follow these patients during many years, irrespective of their disease state, which reduces the 
number of patients lost to follow-up. All these factors make the patient population of study III 
and IV highly representative of the whole spectrum of the disease and its prognosis and we met 
the qualifying criteria described by d‟Amico for this kind of studies (280). 
 
Definition of renal outcome 
The optimal definition of renal outcome for the identification of patients with IgAN at high risk 
for severe disease progression has yet to be identified. During the past decades, different 
surrogate outcome variables have been used to overcome the limitations in follow-up periods for 
clinical and observational studies. In our analyses, we used varying outcome definitions as 
described on page 22, to some extent following trends in the literature when these studies were 
planned. CKD stage 3b+ was introduced as a new endpoint-definition in the analyses described 
in the „Additional results‟ section as it is hypothesized that renal disease progression in patients 
with more advanced renal failure may be less specific to the underlying disease. This outcome 
definition might be worth evaluating as a surrogate marker for interventional studies with regard 
to disease-specific treatment. 
The rate of annual renal function decline (eGFR slope) was used as a measure of the severity of 
renal disease progression in studies III and IV in addition to hard or surrogate endpoints. It is 
generally accepted that progression to renal failure in IgAN is linear (281) with a higher eGFR 
slope in patients with preceding glomerular and interstitial injury, consistent with the 
hyperfiltration hypothesis of renal disease progression earlier described in this thesis. The annual 
eGFR decline is widely used as an outcome variable in recent studies (89, 276, 277, 281).  
However, some patients have accelerated renal function decline that can appear early or late in 
the disease course, as illustrated by the individual cases described in the „Additional results‟ 
section. This could be caused by crescent formation, by increasing vulnerability of remnant 
nephrons due to oxidative stress and inflammatory mechanisms associated with advanced renal 
failure, or by currently unknown mechanisms. Notably, the renal progression rate is sometimes 
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slow, despite the presence of advanced renal failure. This is presumably more often the case in 
patients diagnosed at higher age. 
 
Statistical methods 
Survival analysis was applied in studies II, III and IV as in most of the studies in the literature 
due to „time‟ being an important factor for renal outcome in IgAN. The relatively low number of 
severe outcomes limited the validity of heavily adjusted models for the exploration of possible 
confounders, and contributed to wide confidence intervals in some of our calculations. 
To deal with the non-normal distribution of the investigated potential biomarkers, threshold 
models were used in studies II, III and IV. In study IV and in our additional analyses we also 
used log-transformed values as continuous variables in the linear regression models.  
In the multivariable regression models in study IV, clinically relevant increases in the respective 
variables were used for stratification. 
 
Estimation of glomerular filtration rate  
In the field of nephrology in adults, the gold standard for GFR measurements in Sweden 
nowadays is the clearance of iohexol or, in the case of intolerance, the clearance of Cr-EDTA. 
However, these methods are expensive and time-consuming and thus inconvenient in clinical 
practice and for yearly evaluation of renal function. The MDRD equation for estimation of GFR, 
based on s- creatinine values, was developed 1999 from the Modification of Diet in Renal 
Disease study, which consisted of 1628 non-transplanted CKD-patients with non-diabetic kidney 
disease. The formula was re-expressed in 2006 for standardized creatinine calibration methods 
(226, 282) and is widely used in research. Estimated GFR by the MDRD formula and GFR 
returned from the clearance of iohexol highly conform in the range of CKD stages 3 – 5 whereas 
the MDRD-eGFR formula to some extent underestimates kidney function in CKD stages 1 – 2. 
The recently launched CKD-EPI equation is considered to provide a more exact estimate of 
kidney function in the range of CKD stages 1 – 2. All creatinine-based estimations of GFR can 
be incorrect in the case of extremities in age or body size, in pregnancy, in severe malnutrition or 
obesity, in vegetarian diet, in skeletal muscle diseases and paraplegia and in rapid changes in 
renal function.  
In study IV we performed a secondary analysis of our data estimating GFR by the CKD-EPI 
formula with regard to the fact that 68% of the patients had CKD stage 1 – 2 at baseline. In fact, 
using the CKD-EPI equation we identified additional patients with more rapid renal function 
decline. Thus, misclassification of patients with severe disease was further reduced and the 
power of the statistical analysis slightly improved.  
 
 
4.2 FINDINGS AND IMPLICATIONS 
Main risk factors for renal function loss in IgAN 
In most reports, including those presented in this thesis, the risk factors with the highest impact 
on renal outcome in IgAN were those associated with advanced renal damage such as reduced 
glomerular filtration rate, established hypertension, persistent high-grade proteinuria and, 
histologically, the severity of glomerular sclerosis and tubular atrophy/ interstitial fibrosis (111, 
283). Renal proliferative changes only slightly improved the predictive value of these factors, 
which in part may be biased by effects of treatment, given the limitations of current therapy in 
modifying chronic sclerotic and fibrotic lesions compared with the potential of antihypertensive 
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and/ or immunosuppressive therapy to modify mesangial and endocapillary hypercellularity (89, 
96, 284-286). Failed or insufficient response to treatment with blockers of the angiotensin-
aldosterone system and immunosuppressives with regard to blood pressure and albuminuria most 
probably reflects preexisting renal damage, providing some explanation to the high predictive 
value of follow-up measurements of these variables for disease outcome. 
 
Additional risk factors for CKD progression that can be targeted by current treatment 
Our studies add to the knowledge about the impact of both traditional and non-traditional 
cardiovascular risk factors on renal disease progression in IgAN. Some of these factors can be 
targeted by optimal supportive treatment to prevent or at least attenuate the development of 
advanced renal damage. 
We identified activated monocytes as one possible source of oxidative stress in IgAN and an in 
vivo inhibitory effect of atorvastatin on monocyte activation (study I). Oxidative stress is one of 
the established non-traditional risk factors associated with cardiovascular disease and seems to 
occur early in CKD (229, 287). The critical role of oxidative stress in the pathogenesis of CKD-
related atherosclerosis involves an enhanced effect of systemic inflammation on vascular 
calcification (288-290) and inflammation may also deplete antioxidants (291). In the kidney, 
reactive oxygen species (ROS) can damage biological macromolecules and contribute to cell 
apoptosis.  
We further demonstrated an association of the apolipoprotein B/apolipoprotein A-I ratio with 
renal outcome, which was found to be independent of renal function and, importantly, also 
independent of serum albumin that biologically can influence the lipid-balance (study II). The 
negative impact of apolipoprotein B on cardiovascular disease is well established, as reviewed by 
Olofsson and Borén (292) and included in international guidelines. The apoB/apoA-I ratio is 
supposed to give additional information on the balance of atherogenic and anti-atherogenic 
lipids, though the use of ratios instead of isolated values as biomarkers for risk assessment is not 
generally accepted.  
In IgAN, fluvastatin-treatment improved proteinuria in parallel with improvements in the lipid 
profile (293, 294). In diabetic patients, lipid-lowering therapy is the most effective step to 
prevent cardiovascular disease in multiple disciplinary treatment approaches (295). In the 
recently published large SHARP trial, treatment with a combination of simvastatin and ezetimibe 
reduced the risk of major atherosclerotic events but not the risk of ESRD or a doubling of 
baseline creatinine (296). Smaller studies suggest that the renoprotective effect of statin-
treatment may be more pronounced in individuals with lower eGFR and an „inflamed state‟, 
characterized by higher serum levels of CRP and soluble tumor necrosis factor receptor 2 (TNFR 
II) (269, 297).  
 
Apoliprotein A-I has been proposed as a possible link between infection and chronic 
inflammation. Burger and Dayer showed that contact-mediated activation of monocytes by 
stimulated T lymphocytes triggers the production of large amounts of TNFα and interleukin-1β 
(IL-1β), both of which are involved in chronic inflammation. Apolipoprotein A-I was found to be 
a specific inhibitor of this reaction, which might explain some of its anti-inflammatory effects 
(298). 
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Figure 13.  Mode of action of apo A-I. In normal condition, the level of HDL in the blood stream is sufficient to 
inhibit the triggering of cytokines in monocytes mediated by direct cellular contact with stimulated T lymphocytes. 
HDL-associated apo A-I binds the stimulating factor (X) at the surface of T lymphocytes hampering the binding 
of the latter with its specific receptor at the monocyte surface, thus inhibiting the production of TNF-α and IL-1β. 
Adapted with permission from Burger and Dayer „High-density lipoprotein-associated apolipoprotein A-I: the 
missing link between infection and inflammation?‟, Autoimmunity Reviews 1 (2002) 111-117. 
 
T-lymphocytes are involved in the pathogenesis of IgAN and a continuous T-cell stimulation 
may contribute to persistent inflammatory activity and faster disease progression in IgAN. Our 
findings of the association of sIL-2Ra levels with renal disease progression and with a higher 
degree of tubular atrophy and interstitial fibrosis support this view. This is in line with the current 
concept that the progression of renal fibrosis is associated with the presence of infiltrating 
mononuclear cells, predominantly T lymphocytes and macrophages (204, 242-244, 299, 300) 
and that T-cells are involved in atherosclerotic processes (301-303). Notably, not only treatment 
with immunosuppressives but also treatments with ACEIs and statins have been shown to 
influence T lymphocyte activity (304-306). The observational character of our study and the 
limited number of patients on lipid-lowering therapy or with a history of immunosuppressive 
treatment did not allow any statistical analysis of the effect of treatment on either sIL-2Ra levels 
or outcome. This will be an interesting question for future randomized trials. 
 
Soluble TNFRs I and II as well as sIL-2Ra are small molecules the size of 55 kDa, 57 kDa and 
45 kDa respectively and their rise in the serum of patients with CKD could be explained both by 
retention and increased production. As presented in the „Additional Results‟ section, log TNFR I 
and log TNFR II correlated to logIL-2Ra and all three markers were associated with renal 
survival independent of the main progression risk factors namely baseline eGFR, time-averaged 
albuminuria and time-averaged MAP (Table 6). The independent predictive values of TNFR I 
and II and sIL-2Ra for renal disease progression in IgAN are new findings. They are in line with 
the hypothesis that plasma TNFR levels in patients with IgAN, and possibly also in patients with 
CKD due to other causes, are not only elevated due to retention when the glomerular filtration 
ratio falls but may also reflect an „inflamed‟ state that increases in lower CKD stages and further 
promotes renal disease progression. Statins have been shown to reduce levels of tumor necrosis 
factor as well as MCP-1, TGFβ, IL-6 and NFκB (170, 307, 308), all involved in the 
inflammatory signaling pathways in progressive renal damage. Further studies are warranted to 
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establish whether the levels of IL-2Ra and TNFR I or II are appropriate considerations in the 
monitoring of the effect of treatment, aimed to reduce the inflammatory burden and to prevent 
the progression of renal failure. 
Interestingly, a recent German pilot study showed that treatment with the herb wormwood 
(Artemisia absinthium) reduced proteinuria in IgAN patients who had proteinuria levels between 
0.5 and 3.5 g/ day despite double RAAS blockade and who had not responded to fish oil 
treatment (309). The authors speculate that this effect might be the result of inhibitory effects of 
wormwood on TNFα and NFκB as has been shown in vitro and in patients with Crohn‟s disease 
(310-312).  
 
The accelerated atherosclerosis process in CKD is not only caused by traditional and non-
traditional cardiovascular risk factors as in the general population, but also by vascular 
calcification related to disturbances in renal function and the CKD-MBD complex. 
Hyperphosphatemia, dietary phosphate load, vitamin D insufficiency and secondary 
hyperparathyreoidism, probably altogether reflected by FGF23 values, increase the risk of 
vascular calcification and CVD. Our study shows a predictive value of FGF23 for persistent 
proteinuria and CKD progression in IgAN and contributes to the concept that disturbances in 
mineral metabolism start early in the course of CKD and should be targeted by dietary 
recommendations and medication. Herein, FGF23 may serve as a marker for decision-making on 
therapeutic approaches as its levels appear to be elevated prior to any detectable abnormalities in 
calcium, phosphorus, PTH or vitamin D metabolism (313).   
In IgAN, treatment with vitamin D has been shown to reduce proteinuria alone or in 
combination with blockers of the RAAS (314, 315). Experimental studies provide support for 
1.25 dihydroxy vitamin D-mediated downregulation of renin and the RAAS via activation of the 
vitamin D receptor (316). It has been suggested that vitamin D may be consumed during 
inflammatory processes, which is supported by the findings that statin-treatment led to increased 
levels of 25 (OH) and 1.25 (OH) vitamin D, possibly through anti-inflammatory actions (317).  
 
Metabolic factors beyond calcium, phosphate and vitamin D have been proposed as determinants 
of FGF23. In our study, FGF23 correlated with BMI and hypertension. In addition to these 
variables, Gutierrez et al also reported on associations with other traditional cardiovascular risk 
factors such as smoking and dyslipidemia (318).  
Uric acid levels have been associated with urinary phosphate excretion as well as with FGF23 
levels in serum, suggesting that circulating FGF23 levels and uric acid may be an early indicator 
of high protein and phosphate intake (318, 319). Elevated uric acid levels have been shown to be 
an independent risk factor for CVD, diabetes, insulin resistance, metabolic syndrome, gout and 
uric acid stone formation and are associated with excessive purine consumption (320). 
Hyperuricemia has usually been interpreted as a marker of renal dysfunction but there is now 
emerging evidence of the pathogenetic role of uric acid in hypertension and renal disease 
progression with activation of the renin-angiotensin-system as one of the mechanisms (321, 322). 
This view will have to be supported by larger interventional studies. In IgAN, hyperuricemia was 
an independent risk factor for renal disease progression and correlated with the severity of 
tubulointerstitial changes (128, 323). In vitro studies have demonstrated that uric acid can 
directly promote human T-cell activation and enhance antigen-specific immune responses (324). 
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The impact of obesity on the progression of CKD has been reviewed by Chalmers et al (325). 
Obesity is characterized by similar cardiovascular risk factors as those found in CKD, including 
oxidative stress, lipid abnormalities and persistent inflammation. These mechanisms may act 
synergistically on renal and cardiovascular outcome in CKD. Tanaka et al have reported on 
significant thickening of the glomerular basement membrane in obese patients with IgAN (326, 
327), which presumably contributes to increased proteinuria. This is supported by earlier studies 
showing that weight loss has beneficial effects on proteinuria (328, 329). Despite BMI not being 
a predictive factor for renal outcome in IgAN in our studies, clinical observations suggest this to 
be true in some individual patients. Changes in body weight during follow-up, as indicated in the 
clinical cases in tables 8 and 9 might have an impact on renal outcome both in the case of weight 
gain and when BMI decreases as a consequence of lifestyle changes or gastric surgery. 
 
Renal histopathological markers of inflammation might improve the predictive value of 
histopathological findings for renal disease progression and response to therapy. In the current 
version of the International Oxford classification immunostaining methods were not included, as 
the goal was to develop a classification that is simple and can be widely applied in clinical 
practice. For future research purposes, however, more information on disease promoting 
mechanisms is proposed to be obtained by such methods. A reevaluation of renal biopsies from 
patients included in the earlier performed randomized controlled intervention trials may provide 
valuable information on histopathological and immunological markers for changes that are 
susceptible for treatment.  
Recommendations for the performance of repeated biopsies are lacking and the risks associated 
with this procedure need to be considered.  
 
Despite the strong association found between the degree of tubulointerstitial fibrosis and worse 
prognosis in IgAN and other forms of renal disease, there is nevertheless some hope provided 
from experimental studies that fibrotic and even sclerotic histopathological changes might not 
be as irreversible as previously thought (330, 331). RAAS blockade decreased fibrosis both in 
animal models (330) and in patients with mesangial proliferative glomerulonephritis (332). As 
reviewed by Chatziantoniou and Dussaule, future therapies like growth factor inhibitors may be a 
complement to conventional drugs with anti-fibrinogenic potential such as RAAS blockers and 
statins (331). 
  
What is the impact of persistent severe microhematuria on renal disease progression in 
IgAN? In the risk prediction score and the decision tree model proposed by Goto et al, the degree 
of microhematuria has been included as one of the variables (273, 333). However, until now, the 
prognostic impact of persistent or increasing degrees of microscopic hematuria on renal outcome 
in IgAN has been suggested but is not yet proven (106, 271, 334). The prognostic value of 
urinary erythrocytes may be greater in the early stages of the disease (279). There are pitfalls in 
quantifying hematuria which may contribute to the inconsistent results. Moreover, hematuria 
may be both an indicator of the severity and chronicity of the underlying glomerular injury and, 
at the same time, a promoter of tubular injury through hemoglobin-induced oxidative stress 
(335).  In the field of vasculitis and lupus nephritis, urinary dipstick findings and/or urinary cell 
counts, in addition to other clinical markers and histopathological findings, are routinely 
integrated in the assessment of inflammatory activity and recommendations for treatment. This is 
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still not the case for IgAN. Disappearance of hematuria, on the other hand, has been added to the 
definition of complete remission also in this kind of glomerular disease (336). 
In our studies we did not include the degree of hematuria in the prediction models due to the lack 
of clinical data. During the first years of this follow-up study, urinary dipsticks or cell counts 
were not routinely included in the parameters assessed alongside follow-up visits. There are also 
difficulties in the interpretation of these findings in the presence of hypertensive vessel changes, 
frequently found in the renal biopsy specimens of patients with IgAN.  
 
In summary, systemic inflammation as well as metabolic factors are involved in renal disease 
progression in IgAN and can be targeted by current therapy. There is a great need for further 
studies evaluating serum, urinary and histological inflammatory markers regarding their 
usefulness in the monitoring of treatment in clinical practice. Treatment with statins as well as 
vitamin D supplementation have led to the amelioration of proteinuria, independent of 
ACEI/ARB treatment, probably through analogous effects on inflammatory pathways (337). 
Evidence is still lacking to allow for the inclusion of these medications in general treatment 
recommendations targeted at lowering proteinuria. Nevertheless, the increased risk of CVD in 
patients with reduced renal function usually implies indications for this kind of treatment beyond 
the indication of proteinuria. The additional therapeutic value of uric acid lowering treatment, 
antioxidants, herbs and dietary recommendations in the attenuation of renal disease progression 
has to be further proven.  
 
Hereditary risk factors – the role of hypertension 
Hypertension is highly prevalent not only in patients with IgAN but also in their closest relatives 
as shown in our patient cohort. In a small French study, a family history of hypertension was 
linked to nephrosclerotic changes in renal biopsies from patients with IgAN and was an indicator 
for an unfavorable prognosis (338). This opens for the speculation that a hereditary 
predisposition for hypertension may increase the vulnerability for IgAN. Alternatively, 
hypertension and IgAN are caused by similar predisposing factors. Interestingly, Yamamoto et al 
found an association of IgAN disease progression with gene polymorphisms linked to 
cardiovascular disease (339, 340).    
 
Risk prediction in individual patients 
All the risk factors and scoring systems described in this thesis only predict renal disease 
progression in IgAN to some extent. Additional disease promoting mechanisms still have to been 
explored as exemplified by the clinical cases where the renal disease is highly progressive 
despite optimized supportive therapy. Moreover, it is somewhat problematic to evaluate the value 
of a factor at baseline for prediction of later outcome if this factor is supposed to change during 
the follow-up period as is suggested for the variables apoB/apoA-I ratios, aIL2-Ra, FGF23 and 
markers of oxidative stress. This is illustrated by the now well-documented findings that the 
degree of albuminuria and blood pressure during follow-up has a considerably higher impact on 
renal outcome than baseline values and by the fact that the independent predictive value of 
proliferative histopathological findings in the Oxford classification was attenuated by adjustment 
for immunosuppressive treatment and could not be reproduced in several similar-sized validation 
studies (89, 91).  
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Due to the complexity of interacting mechanisms involved in the progression of CKD and CVD, 
a single biomarker cannot be expected to have more than modest value in the overall risk 
prediction of either renal or cardiovascular events. Epidemiologic approaches that include a 
combination of multiple risk factors, including metabolic parameters, are supposed to improve 
risk assessments and need to be further evaluated by larger clinical studies regarding their 
usefulness in the targeting and monitoring of treatment.  
Low attendance to therapy and life-style recommendations always presents a complicating factor 
in a group of patients, which might be a special problem in young individuals affected by kidney 
disease, usually not associated with overt clinical symptoms early in the disease course. This 
should be overcome in most cases through the advantages of a long-lasting patient-doctor 
relationship in this kind of chronic, slowly progressive disease and through a team-approach 
including nurses, dieticians, physiotherapists and psychologists in the clinical care. 
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5 CONCLUSIONS AND FUTURE PERSPECTIVES 
 
A diagnosis of IgAN implicates a considerable risk of chronic renal failure and premature 
cardiovascular disease. Until further understanding of disease mechanisms and how those can be 
addressed or even prevented by disease-specific therapy, a multidisciplinary treatment approach 
is needed to attenuate renal disease progression and to reduce cardiovascular morbidity and 
mortality. The findings in the present work contribute to the conception that similar mechanisms 
are involved in the development of atherosclerosis and glomerulosclerosis and that persistent 
activation of the immune system has an impact on the rate of renal function decline. Moreover, in 
a pilot study, we illuminate one of the possible mechanisms by which statin treatment could 
attenuate oxidative stress in chronic inflammatory renal disease. 
 
Specifically, based on the different study results, we conclude that: 
 
 Activated circulating monocytes might be one of the sources of oxidative stress in 
chronic inflammatory kidney disease.  
 
 One of the pleiotropic effects of statins, regarding the protection from progressive 
atherosclerosis and glomerulosclerosis, seems to be a direct effect on monocytes by 
reducing their production of reactive oxygen species. 
 
 Measurement of the apolipoprotein B/apolipoprotein A-I ratio, easily applied in clinical 
practice without the need of a fasting condition, can help to identify patients with 
increased risk of renal deterioration. This should lead to a multidisciplinary treatment 
approach targeted at this variable: dietary recommendations, lipid lowering medication, 
excess weight reduction, physical exercise, smoking cessation among others.   
 
 A high plasma level of sIL-2Ra is predictive of renal disease progression in IgAN, 
providing further support for the view that IgAN is a T cell-driven disease. Further 
studies are warranted to evaluate whether sIL-2Ra levels could be a useful marker in the 
monitoring of effect-of-treatment, aimed to prevent the progression of interstitial fibrosis 
and progressive glomerulosclerosis in this patient group. 
 
 Circulating FGF23 is associated with albuminuria and CKD progression in patients with 
IgAN. This study extends the role of FGF23 as a predictive biomarker for CKD 
progression exclusively in the IgAN population and poses the question whether FGF23 
modifies albuminuria as part of an „off-target‟ effect that has been postulated, but not yet 
proven. 
 
 Evaluation of risk factors in our studies confirms earlier findings establishing time-
averaged proteinuria as being the strongest variable that influences the rate of renal 
disease progression. 
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Finally: Despite improvements in the care of patients with IgAN during the last decades, due to 
increasing knowledge about mechanisms involved in renal disease progression in general and, 
possibly, due to a wider use of immunosuppressives, these individuals still constitute a high 
percentage of all patients in renal replacement therapy. Much more research is needed to find 
ways of specifically intervening disease initiating and maintaining mechanisms. Newer treatment 
approaches, currently under investigation, target complement, Toll-like receptors, antigen-
presentation by dendritic cells or proteasomes, NfκB, antigen-producing B-cells, cytokine 
signaling and cell proliferation (341). The genetic profile not only may give a hint about 
adequate treatment approaches but also may reveal different mechanisms predominantly 
involved in the initiation and maintenance of IgAN in different patients and different ethnicities. 
 
Further analyses of the yearly collected blood and urine samples in our study population will 
increase our knowledge on the value of repeated measurements of clinical biomarkers in the 
assessment of the renal and cardiovascular risk in IgAN patients and the monitoring of optimal 
treatment. This will also be reinforced by our planned investigations of the vascular status of 
patients with IgAN at different time points during the disease course, in correlation to clinical 
and biochemical findings.  
These kinds of investigations are supposed to help in the detailed characterization of patients to 
be included in interventional studies for the evaluation of more specifically targeted and tailored 
therapy. In the future, hopefully, a diagnostic kit of biomarkers that are available in clinical 
practice will help the clinician to decide on more individualized therapy aimed to prevent both 
renal failure and cardiovascular disease in patients with IgAN.  
 
As IgAN is a relatively rare disease with a variety of clinical manifestations, new landmarks can 
only be reached through national and international collaboration. The increasing size of the 
International IgA Nephropathy Network, founded in 1987, and the ERA-EDTA initiated 
Immunonephrology Working Group under the leadership of Professor Rosanna Coppo have 
already led to a number of European and International collaboration projects in IgAN. Together, 
these initiatives have the potential to improve our diagnostic and therapeutic opportunities in the 
field of IgAN, similar to the work done in other forms of inflammatory renal disease such as 
ANCA associated vasculitis or systemic lupus erythematosus. 
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6 SUMMARY IN SWEDISH/ POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Glomerulonefrit (GN) är huvudorsaken till kronisk njursvikt hos patienter som är dialysberoende eller 
njurtransplanterade och IgA nefrit (IgAN) är den vanligaste enskilda GN diagnosen. Patienter med nedsatt 
njurfunktion och/eller proteinuri har en ökad risk för tidig utveckling av hjärt-kärlsjukdom. Eftersom 
liknande patogenetiska mekanismer anses vara involverade i fortskridandet av ateroskleros och 
glomeruloskleros, var syftet med denna avhandling att studera, till vilken grad kända traditionella och 
icke-traditionella kardiovaskulära riskfaktorer också indikerar en ökad risk att utveckla njursvikt hos 
patienter med en enhetlig diagnos av IgAN.  
Kronisk inflammation betraktas som en viktig bidragande orsak till fortskridande njurskada. Vid IgAN har 
störningar i det medfödda och det förvärvade immunsystemet påvisats där T-lymfocyter har en betydande 
roll. Vi har därför också undersökt om plasma-nivåer av löslig interleukin-2 receptor (sIL-2Ra), en 
föreslagen markör för kontinuerlig T-cells stimulering, kan prediktera njurfunktionsförlust vid IgAN. 
 
Studie I är en pilot studie som undersöker aktiverade monocyter som en potentiell källa till oxidativ stress 
vid IgAN. Monocyter i perifert blod från 16 patienter med IgAN och 16 friska kontrollpersoner 
stimulerades in vitro och produktionen av syre-radikaler mättes med hjälp av flödescytometri. Patienterna 
behandlades därefter under en månad med en daglig dos av 20 mg atorvastatin, varefter monocyternas 
produktion av syre-radikaler efter in vitro stimulering kvantifierades på nytt. Vi fann att monocyter från 
patienter med IgAN uppvisade en högre produktion av syre-radikaler jämfört med celler från friska 
kontroller och att statin-behandling ledde till en reducering av densamma. 
 
I studie II undersökte vi 70 patienter med IgAN och kronisk njursvikt i stadium 1 – 3 [beräknad 
glomerulär filtrations hastighet (eGFR) > 30ml/min/1,73m²] och 70 ålders- och könsmatchade friska 
personer med avseende på kvoten av apolipoprotein B och apolipoprotein A-I (apoB/apoA-I) i blodet, 
vilken avspeglar balansen mellan de blodfetter som bidrar till, och de som motverkar, ateroskleros-
utvecklingen. Patienter med IgAN hade högre serum-nivåer av apoB/apoA-I i jämförelse med de friska 
kontrollerna och en apoB/apoA-I kvot över de föreslagna gränsvärdena av 0,9 för män och 0,8 för kvinnor 
var förknippad med en ökad risk för utveckling av terminal njursvikt hos IgAN patienterna, efter en 
uppföljningsperiod av i genomsnitt 3,8 år.  
 
Studie III omfattade 194 patienter med IgAN, av vilka 179 patienter med kronisk njursvikt i stadium 1 – 
4 (eGFR > 15ml/min/1,73m²) hade följts kliniskt under upp till 16 år (medianvärde 52 månader). Plasma-
koncentrationen av sIL-2Ra var högre hos patienterna jämfört med hos 84 friska kontrollpersoner. Nivåer 
av sIL-2Ra i högsta tertilen indikerade en ökad risk för njurfunktionsförsämring hos IgAN patienterna och 
sIL-2Ra nivåerna korrelerade även till den årliga förlusten av eGFR. Hos 51 patienter hade njurbiopsin 
genomförts maximalt 2 år före analysen av sIL-2Ra och granskats i enlighet med den nya internationella 
Oxford-klassifikationen. I denna subgrupp av patienter korrelerade sIL-2Ra nivåerna med förekomsten av 
> 25% tubulär atrofi/ interstitiell fibros (graderad som T 1 – 2 enligt Oxford- MEST klassifikationen), 
vilket var statistiskt signifikant även efter justering för njurfunktionen. 
 
Studie IV inkluderade 180 IgAN patienter med kronisk njursvikt i stadium 1 – 4 vilka hade följts 
prospektivt (median 55 månader). Vi analyserade serum-nivåer av det fosfat- reglerande hormonet FGF23 
(fibroblast growth factor 23), en nyckelspelare i symptomkomplexet av kronisk njursvikt och medföljande 
störningar i mineral-metabolism och skelettuppbyggnad. FGF23 koncentrationen var associerad med en 
allvarligare grad av njurfunktionsförsämring och korrelerade även till graden av albumin-utsöndringen i 
urinen vid inklusion och under uppföljningstiden. 
 
Sammanfattningsvis kunde vi visa att flera riskfaktorer för ateroskleros också är riskfaktorer för 
njurfunktionsförsämring hos patienter med IgAN, oberoende av de kända huvudsakliga riskfaktorerna 
proteinuri och högt blodtryck. En kontinuerlig aktivering av T- celler är en möjlig bidragande faktor till 
fortskridande njursvikt vid IgAN.  De undersökta potentiella biomarkörer kan vara av värde för att 
monitorera behandlingen hos patienter med IgAN.       
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